1. Introduction {#sec1-cancers-11-00628}
===============

The recognition of the importance of the tumor -- host interactions in the prognosis of cancer patients significantly predates the current era of cancer immunotherapy. The gradual deciphering of these complex interactions is summarized in the conceptual framework laid out by Hanahan and Weinberg \[[@B1-cancers-11-00628]\], where immunoediting is suggested as a driving force guiding tumor progression. Exploiting these advances only in part, cancer treatment by the inhibition of negative regulators has revolutionized the management of multiple human malignancies, culminating with the award of the 2018 Nobel Prize in Physiology or Medicine -- the first ever bestowed upon research related to an anticancer therapy \[[@B2-cancers-11-00628]\].

Beyond its utility as a treatment target, immune response to cancer has also been a subject of research concerning its role as both a prognostic and predictive biomarker. As an example, higher tumor-infiltrating lymphocyte (TIL) counts and expression of immune function genes have been shown to predict better outcomes in most breast cancer (BC) subtypes and increased rates of pathologic complete remission (pCR) following the administration of neoadjuvant chemotherapy (NACT) for early BC (EBC) \[[@B3-cancers-11-00628],[@B4-cancers-11-00628]\]. In metastatic BC (MBC), TIL enumeration has not proven to be as successful \[[@B5-cancers-11-00628]\], since TIL counts have been shown to be lower in metastatic sites compared to the primary tumor \[[@B6-cancers-11-00628]\]. On the other hand, Programmed Cell Death Protein 1 (PD-1) and its ligand PD-L1, as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have been extensively evaluated as putative markers of response to immunotherapy with PD-1/PD-L1 and CTLA-4 blockade, respectively \[[@B7-cancers-11-00628],[@B8-cancers-11-00628]\]. Although data stemming from randomized clinical trials in various human cancers are conflicting, in MBC only one phase 3 trial has been reported demonstrating increased benefit from the combination of atezolizumab and nab-paclitaxel compared to nab-paclitaxel alone in patients whose tumors expressed PD-L1 \[[@B9-cancers-11-00628]\]. PD-1/PD-L1 and CTLA-4 checkpoint inhibitors are already the focus of advanced clinical trials (reviewed by Adams et al. \[[@B10-cancers-11-00628]\]).

Despite the aforementioned exciting developments, it is clear that only a fraction of the potential immunologic therapeutic targets has been comprehensively characterized. Unfortunately, research on immunotherapy for BC has lagged behind due to its perceived lower immunogenicity \[[@B11-cancers-11-00628]\]. Nevertheless, a growing body of literature focusing on a large number of co-stimulatory and inhibitory molecules suggests that the field of cancer immunotherapy in general, and BC in particular, is only in its early stages of development. Herein, we summarize available data on novel immunotherapy targets with a focus on BC ([Figure 1](#cancers-11-00628-f001){ref-type="fig"}).

2. Markers Predominantly Expressed on T-lymphocytes {#sec2-cancers-11-00628}
===================================================

2.1. LAG-3 {#sec2dot1-cancers-11-00628}
----------

Lymphocyte activation gene-3 (LAG-3) is a cluster of differentiation 4 (CD4) related negative regulator of immune response considered as a marker of T-cell exhaustion. It is expressed on both effector and regulatory T-cells, Natural Killer (NK)-cells, B-cells and dendritic cells (DC) \[[@B12-cancers-11-00628],[@B13-cancers-11-00628],[@B14-cancers-11-00628],[@B15-cancers-11-00628],[@B16-cancers-11-00628]\]. Identified LAG-3 ligands are MHC (Major Histocompatibility Complex) class II molecules expressed on antigen presenting cells (APC), LSECTin and Galectin-3 \[[@B17-cancers-11-00628],[@B18-cancers-11-00628]\]. LAG-3 is thought to inhibit the activity and expansion of effector T-cells and enhances the suppressive activity of T-regulatory lymphocytes (Tregs) \[[@B19-cancers-11-00628],[@B20-cancers-11-00628],[@B21-cancers-11-00628],[@B22-cancers-11-00628]\].

Published data on the role of LAG-3 in BC indicate that it is overexpressed in the tumor compared to the adjacent healthy breast tissue \[[@B23-cancers-11-00628],[@B24-cancers-11-00628],[@B25-cancers-11-00628]\], while its overexpression has been associated with improved patient outcomes \[[@B26-cancers-11-00628]\] ([Table 1](#cancers-11-00628-t001){ref-type="table"}). Following promising pre-clinical results, LAG-3 inhibitors are currently being tested in early phase clinical trials including BC, as monotherapy or in combination with chemotherapy or anti-PD-1 therapy ([Table 2](#cancers-11-00628-t002){ref-type="table"}). One phase I/II clinical trial testing IMP321 (Eftilagimod), a recombinant soluble LAG-3 Ig (Immunoglobulin) fusion protein, in combination with weekly paclitaxel as a first line treatment in 30 patients with MBC showed promising results, with a response rate of 50% \[[@B27-cancers-11-00628]\].

2.2. TIM-3 {#sec2dot2-cancers-11-00628}
----------

T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) is a negative regulator of adaptive and innate immune responses. It is expressed on CD8+ and CD4+ T helper 1 cells (Th1 cells), Tregs, NK cells, DC, monocytes and macrophages \[[@B89-cancers-11-00628],[@B90-cancers-11-00628],[@B91-cancers-11-00628],[@B92-cancers-11-00628]\]. Known ligands to TIM-3 are Galectin-9, Ceacam1, HMGB1 (High Mobility Group Box 1) and phosphatidylserine, all expressed by a variety of cells including tumor cells \[[@B93-cancers-11-00628],[@B94-cancers-11-00628],[@B95-cancers-11-00628],[@B96-cancers-11-00628]\]. TIM-3 induces an immunosuppressive environment by suppressing effector Th1 response \[[@B93-cancers-11-00628]\], regulating CD8+ T cell exhaustion \[[@B97-cancers-11-00628]\] and enhancing the regulating function of Tregs \[[@B90-cancers-11-00628],[@B98-cancers-11-00628]\]. It also inhibits the stimulation of the innate immune response by competing with tumor-derived nucleic acids to bind HMGB1 and promoting the expansion of myeloid-derived suppressor cells (MDSC) \[[@B95-cancers-11-00628],[@B99-cancers-11-00628]\].

TIM-3 seems to be upregulated both in BC samples compared to normal adjacent tissue and circulating lymphocytes, possibly through hypomethylation of its promoter \[[@B23-cancers-11-00628],[@B29-cancers-11-00628]\] ([Table 1](#cancers-11-00628-t001){ref-type="table"}). However, expression on immune cells has been reported to vary widely \[[@B29-cancers-11-00628],[@B100-cancers-11-00628]\]. Burugu et al. evaluated TIM-3 IHC expression in 3992 BC samples of all subtypes and found that the TIM-3 intraepithelial TIL infiltration is associated with a better outcome \[[@B32-cancers-11-00628]\]. TIM-3 polymorphisms might also play a role in the susceptibility to, and prognosis of BC \[[@B101-cancers-11-00628],[@B102-cancers-11-00628],[@B103-cancers-11-00628]\].

Drugs targeting TIM-3 are currently being tested in early phase clinical trials including BC, alone or in combination with anti-PD1/PD-L1 check point inhibitors, with no published results yet ([Table 2](#cancers-11-00628-t002){ref-type="table"}).

2.3. VISTA {#sec2dot3-cancers-11-00628}
----------

V-domain Ig suppressor of T cell activation (VISTA) is a negative regulator of the T-cell immune activity functioning both as a ligand and receptor \[[@B104-cancers-11-00628]\]. It has been shown to be expressed by CD4+ and CD8+ T-cells, Tregs, DC, NK-cells, monocytes, macrophages and granulocytes \[[@B105-cancers-11-00628],[@B106-cancers-11-00628]\], as well as tumor cells \[[@B107-cancers-11-00628],[@B108-cancers-11-00628],[@B109-cancers-11-00628]\]. VISTA exerts its immunosuppressive function by decreasing the T-cell production of effector cytokines, diminishing T-cell proliferation and increasing conversion to Tregs \[[@B106-cancers-11-00628]\]. To our knowledge, VISTA's expression and prognostic impact in BC has never been assessed, although a phase 1 clinical trial which enrolls TNBC patients and tests an oral inhibitor of PD-L1, PD-L2 and VISTA is currently ongoing ([Table 2](#cancers-11-00628-t002){ref-type="table"}).

2.4. TIGIT {#sec2dot4-cancers-11-00628}
----------

T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a co-inhibitory molecule expressed on effector, memory and regulatory T-cells, follicular helper (Tfh) and NK-cells \[[@B110-cancers-11-00628],[@B111-cancers-11-00628]\]. It competes with CD223 to bind its two identified ligands, CD155 and CD112, expressed on APC, fibroblasts, endothelial, epithelial cells and also on a variety of cancer cells, including BC \[[@B112-cancers-11-00628]\]. TIGIT has different ways of exerting its immunosuppressive action: Direct inhibition of NK-cell function \[[@B113-cancers-11-00628]\], direct inhibition of T-cell activation, proliferation and cytotoxicity by attenuating TCR-driven (T-cell receptor) activation signals \[[@B114-cancers-11-00628]\] and indirect inhibition of T-cells by promoting the maturation of immunoregulatory DCs \[[@B111-cancers-11-00628]\]. It also promotes the Tregs function by being a direct target to FoxP3 (Forkhead box P3) and inducing an enhanced suppressive function \[[@B115-cancers-11-00628],[@B116-cancers-11-00628]\].

TIGIT expression in BC has only been assessed at the transcriptomic level, with most studies showing overexpression \[[@B23-cancers-11-00628],[@B31-cancers-11-00628],[@B33-cancers-11-00628],[@B117-cancers-11-00628]\] ([Table 1](#cancers-11-00628-t001){ref-type="table"}). In one study, overexpression was correlated with improved patient survival in TNBC \[[@B33-cancers-11-00628]\], leading to the development of antibodies targeting TIGIT in combination with PD-1 blockade ([Table 2](#cancers-11-00628-t002){ref-type="table"}).

2.5. GITR {#sec2dot5-cancers-11-00628}
---------

Glucocorticoid-induced TNFR-related protein (GITR) is a co-stimulatory member of the tumor necrosis factor (TNF) receptor superfamily expressed constitutively on all T-cells \[[@B118-cancers-11-00628],[@B119-cancers-11-00628]\]. It is also expressed on NK-cells, eosinophils, basophils, macrophages and B-cells \[[@B120-cancers-11-00628]\]. Its activating ligand is the GITR ligand (GITRL), expressed on APC and endothelial cells \[[@B121-cancers-11-00628],[@B122-cancers-11-00628]\]. Upon binding, GITR exerts an immunostimulatory activity by directly enhancing T-cell proliferation and effector functions \[[@B123-cancers-11-00628],[@B124-cancers-11-00628]\]. It also indirectly enhances the effector T-cell function by decreasing the intratumoral Treg numbers and suppressive function \[[@B125-cancers-11-00628],[@B126-cancers-11-00628]\]. By avoiding activation-induced cell death, it also promotes an increase in memory T-cells \[[@B127-cancers-11-00628]\].

Cari et al. assessed GITR mRNA expression in 3169 BC patients of all subtypes and found an overexpression in 42% of the cases \[[@B31-cancers-11-00628]\]. Other studies demonstrated that expression is increased in both infiltrating \[[@B34-cancers-11-00628]\] and circulating Tregs of BC patients \[[@B35-cancers-11-00628],[@B37-cancers-11-00628]\]. Interestingly, GITR seems to also be overexpressed in CD4+ T-cells in BC-infiltrated lymph nodes \[[@B36-cancers-11-00628]\] ([Table 1](#cancers-11-00628-t001){ref-type="table"}).

BMS-986156, a GITR agonistic monoclonal antibody, in combination with nivolumab has demonstrated an acceptable safety profile and promising antitumor activity in advanced solid tumors \[[@B82-cancers-11-00628]\]. Other agonist molecules targeting GITR are currently being tested in early phase clinical trials ([Table 2](#cancers-11-00628-t002){ref-type="table"}).

2.6. B7-H3 {#sec2dot6-cancers-11-00628}
----------

B7 homolog 3 (B7-H3) is a member of the B7 family of immunomodulatory ligands. It is not spontaneously expressed in peripheral blood mononuclear cells but can be induced upon stimulation in APC, T-cells and NK-cells \[[@B128-cancers-11-00628]\]. It is widely expressed in healthy solid organs and several malignancies, including BC \[[@B129-cancers-11-00628]\]. Interestingly, it is also expressed by tumor-associated endothelial cells \[[@B45-cancers-11-00628]\]. Although B7-H3 was initially seen as a co-stimulatory molecule, which increases CD4+ and CD8+ proliferation and enhances T cell cytotoxicity \[[@B129-cancers-11-00628],[@B130-cancers-11-00628]\], the majority of recent studies highlight its co-inhibitory role. Indeed, it appears to downregulate T-cell proliferation and cytokine production \[[@B131-cancers-11-00628]\], Th1 and Th2-mediated immune reactions \[[@B132-cancers-11-00628]\] and inhibit NK cells activity \[[@B133-cancers-11-00628]\]. Moreover, B7-H3 seems to influence cancer progression beyond its immunoregulatory role, by promoting migration, invasion and angiogenesis \[[@B134-cancers-11-00628],[@B135-cancers-11-00628]\].

B7-H3 expression in BC has been extensively studied and demonstrated to confer worse prognosis \[[@B41-cancers-11-00628],[@B42-cancers-11-00628]\] ([Table 1](#cancers-11-00628-t001){ref-type="table"}). As a result, two antagonist drugs -- a monoclonal antibody (enoblituzumab) and a dual-affinity re-targeting (DART^®^) protein (MGD009) -- are currently under evaluation in early phase clinical trials including BC ([Table 2](#cancers-11-00628-t002){ref-type="table"}).

2.7. ICOS {#sec2dot7-cancers-11-00628}
---------

Inducible T cell co-stimulator (ICOS) is a specific T-cell molecule of the B7-binding CD28 family, expressed on activated T-cells after TCR engagement and enhanced by CD28 co-stimulation \[[@B136-cancers-11-00628],[@B137-cancers-11-00628]\]. Its only ligand is ICOS-L, mainly expressed on APC \[[@B138-cancers-11-00628],[@B139-cancers-11-00628],[@B140-cancers-11-00628]\] but also on endothelial and lung epithelial cells \[[@B141-cancers-11-00628],[@B142-cancers-11-00628]\]. Although typically seen as an immune co-stimulatory pathway, notably through promoting cell proliferation/differentiation, enhancing Th1/Th2 function and facilitating T-dependent B-cell activation \[[@B136-cancers-11-00628],[@B137-cancers-11-00628],[@B143-cancers-11-00628]\], ICOS/ICOS-L interaction might also have an immunosuppressive role through the accumulation of Tregs and secretion of IL-10 \[[@B46-cancers-11-00628],[@B144-cancers-11-00628]\].

In a study by Faget et al., BC patients overexpressing ICOS had a significantly worse survival in the univariate but not multivariate analysis \[[@B46-cancers-11-00628]\], while certain ICOS gene polymorphisms have also been associated with increased BC susceptibility in Chinese populations \[[@B145-cancers-11-00628],[@B146-cancers-11-00628]\] ([Table 1](#cancers-11-00628-t001){ref-type="table"}). Ongoing trials of agents targeting ICOS are shown in [Table 2](#cancers-11-00628-t002){ref-type="table"}.

2.8. 4-1BB (CD137) {#sec2dot8-cancers-11-00628}
------------------

4-1BB (CD137) is a member of the TNF receptor superfamily, widely expressed on adaptive and innate immune cells like effector, helper and regulatory T-cells \[[@B147-cancers-11-00628],[@B148-cancers-11-00628]\], B-cells \[[@B149-cancers-11-00628]\], NK-cells \[[@B150-cancers-11-00628],[@B151-cancers-11-00628]\], DCs \[[@B152-cancers-11-00628]\], neutrophils, eosinophils, mast cells, monocytes and macrophages \[[@B153-cancers-11-00628]\]. It is also expressed by a variety of other non-immunological cells, including endothelial and malignant hematological cells \[[@B154-cancers-11-00628]\]. It exerts a co-stimulatory action upon ligation with its ligand 4-1BBL, resulting in enhanced T-cell and NK-cell proliferations, production of pro-inflammatory cytokines and cytotoxicity \[[@B150-cancers-11-00628],[@B155-cancers-11-00628],[@B156-cancers-11-00628]\] and the inhibition of activation-induced cell-death in T-cells \[[@B157-cancers-11-00628]\].

Two studies using gene-expression datasets demonstrated that 4-1BB is overexpressed in BC and is associated with better prognosis \[[@B31-cancers-11-00628],[@B47-cancers-11-00628]\] ([Table 1](#cancers-11-00628-t001){ref-type="table"}).

Monoclonal agonist antibodies are currently being tested in early phase clinical trials including BC ([Table 2](#cancers-11-00628-t002){ref-type="table"}). Two early-phase studies (NCT00351325 and NCT00309023) raised concerns due to two hepatotoxicity-related deaths, though not replicated in a follow-up phase 1 study \[[@B158-cancers-11-00628]\].

2.9. CD27 and CD70 {#sec2dot9-cancers-11-00628}
------------------

CD27 and its only ligand CD70, are members of the TNF receptor and ligand superfamily that interact exclusively with each other. CD27 expression on T-cells is tightly regulated, with upregulation upon activation after the TCR stimulation followed by downregulation once the effector T-cell differentiation is acquired \[[@B159-cancers-11-00628]\]. CD27 is also expressed on B-cells (germinal center and memory B-cells) and NK-cells \[[@B160-cancers-11-00628],[@B161-cancers-11-00628],[@B162-cancers-11-00628]\]. CD70 expression on immune cells is also tightly regulated and is present on activated T-cells, stimulated B-cells, mature DC and NK-cells \[[@B163-cancers-11-00628],[@B164-cancers-11-00628],[@B165-cancers-11-00628],[@B166-cancers-11-00628]\]. Interestingly, CD70 has also been found to be expressed in various hematological, sarcoma and carcinoma cells including BC \[[@B167-cancers-11-00628]\]. The CD27-CD70 pathway exerts its co-stimulatory activity in great part through CD27 interaction with TNF receptor associated factors (TRAF), resulting in the activation of transcription factors of MAPK (Mitogen-activated Protein Kinase) and NFκB (Nuclear Factor kappa-light-chain-enhancer of activated B-cells) family. This leads to the expansion and survival of activated T cells \[[@B168-cancers-11-00628],[@B169-cancers-11-00628],[@B170-cancers-11-00628],[@B171-cancers-11-00628],[@B172-cancers-11-00628],[@B173-cancers-11-00628]\]; differentiation to memory and effector T-cells \[[@B173-cancers-11-00628],[@B174-cancers-11-00628],[@B175-cancers-11-00628]\]; activation of NK-cells \[[@B176-cancers-11-00628],[@B177-cancers-11-00628]\]; and differentiation plus activation of B-cells \[[@B178-cancers-11-00628],[@B179-cancers-11-00628],[@B180-cancers-11-00628]\].

CD70 protein expression in BC was assessed in two studies with contrasting results \[[@B49-cancers-11-00628],[@B50-cancers-11-00628]\] ([Table 1](#cancers-11-00628-t001){ref-type="table"}). Of interest, Liu et al. demonstrated that a high CD70 expression was correlated with worse lung metastasis-free survival, but not with other metastatic sites following relapse of EBC. In addition, gene expression studies showed that CD70 was overexpressed in basal-like compared to Luminal A cancers and that overexpression after NACT was associated with a better outcome \[[@B51-cancers-11-00628],[@B181-cancers-11-00628]\].

Two antibodies, ARGX-110 targeting CD70 and CDX-1127 (Varlilumab) targeting CD27 are currently in early phase clinical trials. In addition, a trial is testing the safety and activity of administering peripheral blood lymphocytes transduced with a CD70-binding Chimeric Antigen Receptor (CAR) to patients with CD70-expressing cancers ([Table 2](#cancers-11-00628-t002){ref-type="table"}).

2.10. OX40 and OX40L {#sec2dot10-cancers-11-00628}
--------------------

OX40 (CD134) and OX40L are members of the TNF superfamily. OX40 is constitutively expressed on Tregs and transiently induced on activated CD4+ and CD8+ T-cells following TCR stimulation \[[@B182-cancers-11-00628],[@B183-cancers-11-00628],[@B184-cancers-11-00628]\]. It has also been reported to be expressed by neutrophils, NK-cells and NKT-cells \[[@B185-cancers-11-00628],[@B186-cancers-11-00628],[@B187-cancers-11-00628]\]. Its ligand, OX40L, is expressed on professional APC, NK-cells, Langerhans cells, vascular endothelial cells, monocytes, neutrophils and mast cells. Like OX40, it is upregulated upon activation \[[@B188-cancers-11-00628],[@B189-cancers-11-00628],[@B190-cancers-11-00628],[@B191-cancers-11-00628],[@B192-cancers-11-00628],[@B193-cancers-11-00628],[@B194-cancers-11-00628],[@B195-cancers-11-00628]\]. OX40-OX40L interaction, like other TNF members, exerts a co-stimulatory effect through interacting with TRAF, which impacts CD4+ and CD8+ T cells by enhancing their proliferation and survival, generating memory cells, enhancing their effector function and promoting differentiation into Th1, Th2 and Th17 cells through various cytokines production \[[@B196-cancers-11-00628],[@B197-cancers-11-00628],[@B198-cancers-11-00628],[@B199-cancers-11-00628],[@B200-cancers-11-00628],[@B201-cancers-11-00628],[@B202-cancers-11-00628],[@B203-cancers-11-00628]\].

Several studies have assessed OX40 expression in BC, showing an expression varying from 15.5% to 85% of cases ([Table 1](#cancers-11-00628-t001){ref-type="table"}). Interestingly, Xie et al. reported expression on cancer cells while all the other studies reported expression on TILs \[[@B52-cancers-11-00628]\]. Consequently, a number of agonistic monoclonal antibodies targeting OX40 and a mRNA encoding OX40L (injected intra-tumorally) are currently being tested in early phase clinical trials including BC, alone or in combination with other immunotherapies. ([Table 2](#cancers-11-00628-t002){ref-type="table"})

2.11. BTLA {#sec2dot11-cancers-11-00628}
----------

BTLA (B and T Lymphocyte Attenuator) is an inhibitory Ig-domain-containing glycoprotein receptor of the CD28 superfamily expressed on activated T-cells, B-cells, Tfh cells, macrophages, DC, NKT-cells and NK-cells \[[@B204-cancers-11-00628],[@B205-cancers-11-00628],[@B206-cancers-11-00628],[@B207-cancers-11-00628],[@B208-cancers-11-00628]\]. Its only proven ligand is HVEM (Herpes Virus Enter Mediator), a member of the TNF receptor family, expressed on CD4+ and CD8+ T-cells (strongly on resting T cells, downregulated upon activation), naïve and memory but not activated B-cells, monocytes, DC, solid organs, tumor-associated endothelial cells or on various cancer cells including BC \[[@B209-cancers-11-00628],[@B210-cancers-11-00628],[@B211-cancers-11-00628],[@B212-cancers-11-00628]\]. BTLA has also been described as a potential receptor for B7-H4 in BC \[[@B213-cancers-11-00628]\]. BTLA exerts its T-cell inhibitory action upon binding HVEM, leading to a decreased T-cell proliferation and cytokine production with a predominant effect on CD4+ cells \[[@B214-cancers-11-00628],[@B215-cancers-11-00628],[@B216-cancers-11-00628],[@B217-cancers-11-00628],[@B218-cancers-11-00628],[@B219-cancers-11-00628]\]. Data concerning its action on B-cell function is scarce but it appears to negatively regulate B-cell activation \[[@B220-cancers-11-00628]\]. Interestingly, BTLA and PD-1 seem to be co-expressed on CD8+ T-cells.

Data concerning BTLA expression in BC is scarce ([Table 1](#cancers-11-00628-t001){ref-type="table"}). Although it seems to be overexpressed at the transcriptomic level, especially in TNBC where it was also associated with improved survival \[[@B57-cancers-11-00628]\], protein expression appeared to be limited in another study \[[@B58-cancers-11-00628]\]. To our knowledge, no clinical trials for therapeutic targeting of BTLA are currently ongoing.

2.12. TLR9 {#sec2dot12-cancers-11-00628}
----------

Toll-like receptors (TLRs) are type I transmembrane glycoproteins of the pattern recognition receptors (PRR). They play a key role in immunity by allowing immune cells to recognize non-self or altered-self molecular patterns, activating the innate immune response and coordinating the innate and adaptive immune responses. The most studied member in BC is the intracellular receptor TLR9.

TLR9 is a DNA receptor that migrates from the endoplasmic reticulum to the endosomal/lysosomal compartment when DNA enters the cell \[[@B221-cancers-11-00628],[@B222-cancers-11-00628]\]. When activated by DNA recognition, TLR9 initiates a signaling cascade \[[@B222-cancers-11-00628],[@B223-cancers-11-00628]\], leading to the activation of various transcription factors like NF-κB and AP-1 (Activator protein 1) \[[@B224-cancers-11-00628]\], thus promoting the transcription of genes that are important for inflammatory and immune responses \[[@B225-cancers-11-00628],[@B226-cancers-11-00628]\]. In addition, it promotes adaptive immunity by enhancing DC maturation and producing a favorable cytokine/chemokine milieu that results in the activation of Th1 and CD8 cytotoxic T lymphocytes as well as by promoting B-cell proliferation \[[@B227-cancers-11-00628],[@B228-cancers-11-00628]\].

TLR9 expression and its prognostic role in BC has been reported by several studies with conflicting results \[[@B60-cancers-11-00628],[@B64-cancers-11-00628]\] ([Table 1](#cancers-11-00628-t001){ref-type="table"}). Nevertheless, it appears that TLR9 is expressed at higher levels in estrogen receptor (ER) negative and high-grade tumors. Regarding the prognostic significance of TLR9 expression, three studies associated high expression with a better outcome \[[@B60-cancers-11-00628],[@B61-cancers-11-00628],[@B64-cancers-11-00628]\], while two other studies reported worse survival \[[@B63-cancers-11-00628],[@B66-cancers-11-00628]\]. Of interest, Karki et al. demonstrated that BC patients have decreased serum levels of TLR9 compared to patients with benign lesions and healthy controls, proposing it as a potential diagnostic biomarker \[[@B229-cancers-11-00628]\]. Moreover, several but not all studies have shown an association between TLR9 gene polymorphisms and BC susceptibility \[[@B230-cancers-11-00628],[@B231-cancers-11-00628],[@B232-cancers-11-00628],[@B233-cancers-11-00628]\].

Therapeutic targeting of TLR9 has proven to be efficient in pre-clinical models of various cancers including BC and many drugs are currently being tested in several cancer types, some of them even reaching phase III (NCT03445533) ([Table 2](#cancers-11-00628-t002){ref-type="table"}).

2.13. The Adenosine Pathway in Breast Cancer {#sec2dot13-cancers-11-00628}
--------------------------------------------

The adenosine pathway is an important peripheral control mechanism for regulating the immune response in order to prevent over-activation and tissue damage. As with other immunoregulatory pathways, cancer cells are capable of hijacking it in order to promote tumor escape. Important components of this pathway are the adenosine receptor A2a (A2aR), through which the extracellular adenosine can activate its intracellular signaling pathway and the ectonucleotidases CD39 and CD73, which participate in extracellular adenosine production by dephosphorylating ATP.

A2aR is a G-protein-coupled receptor expressed on T and NKT-cells, B-cells, monocytes, macrophages, DC, NK-cells, mast cells, eosinophils and platelets \[[@B234-cancers-11-00628]\]. CD73 is a cell-surface enzyme that can also be found as an enzymatically active soluble form. It is widely expressed on immune cells including B-cells, CD8+ and CD4+ T-cells, Tregs, neutrophils, MDSC, monocytes, macrophages, DC and NK-cells \[[@B235-cancers-11-00628]\]. It is also expressed on a wide range of epithelial cells, endothelial cells and cancer cells including BC \[[@B235-cancers-11-00628],[@B236-cancers-11-00628],[@B237-cancers-11-00628]\]. CD39, another cell-surface enzyme which produces adenosine, is also expressed on a variety of immune cells \[[@B238-cancers-11-00628],[@B239-cancers-11-00628],[@B240-cancers-11-00628]\]. It is also expressed on platelets, endothelial cells and cancer cells including lung, melanoma, pancreatic and lymphoma cells \[[@B241-cancers-11-00628],[@B242-cancers-11-00628],[@B243-cancers-11-00628]\]. Like CD73, a soluble catalytically active form of CD39 exists \[[@B244-cancers-11-00628]\]

The adenosine pathway exerts an immunosuppressive action by inhibiting effector T-cell activation \[[@B245-cancers-11-00628]\], proliferation, cytokine production and cytotoxicity as well as promoting their immunosuppressive cytokine production \[[@B246-cancers-11-00628],[@B247-cancers-11-00628]\]. In addition, it promotes Tregs formation \[[@B246-cancers-11-00628]\], inhibits NK-cell antitumor activity \[[@B248-cancers-11-00628]\], NKT-cell production of cytokines \[[@B249-cancers-11-00628]\], macrophage proliferation \[[@B250-cancers-11-00628]\] and DC maturation \[[@B251-cancers-11-00628]\]. It has also been shown to increase the expression of other immune checkpoints \[[@B252-cancers-11-00628]\].

CD73 expression on BC cells ranges from 9 to 84% of the cases and is generally associated with worse outcome, although one study reported contrasting results \[[@B68-cancers-11-00628]\] ([Table 1](#cancers-11-00628-t001){ref-type="table"}). In addition, CD39 is overexpressed both in TILs and circulating T cells of BC patients when compared to healthy controls, but its prognostic value has not been studied.

Numerous pre-clinical studies have demonstrated the efficacy of targeting the adenosine pathway in BC models, leading to the development of A2aR oral inhibitors and antibodies targeting CD73, currently in early phase clinical trials ([Table 2](#cancers-11-00628-t002){ref-type="table"}). CD39 targeting therapies are currently under pre-clinical development but to our knowledge none have yet reached clinical trials.

3. Tumor-Associated Macrophages and Related Markers {#sec3-cancers-11-00628}
===================================================

Tumor-associated macrophages (TAMs) represent a major and heterogeneous distinct immune cell subpopulation in the tumor microenvironment (TME). In many tumor types, including BC, TAMs play a key role in tumor progression, angiogenesis, immune evasion and metastasis \[[@B253-cancers-11-00628]\]. They also interact with other cell types through the secretion of various cytokines which in turn can modify the balance between tumor, stromal, endothelial and immune cells. According to the markers expressed on their cell surface as well as the factors they secrete, TAMs can be divided into two subtypes: a) the classically activated M1-like macrophages which have pro-inflammatory, anti-tumoral properties mainly through the secretion of TNF-a (Tissue Necrosis Factor alpha), IL-1, IL-2, IL-6, IL-12; and b) the selectively activated M2-like macrophages with anti-inflammatory, pro-tumoral phenotype mainly through TGF-β (Transforming growth factor beta), IL-4, IL-10 and IL-13 \[[@B254-cancers-11-00628]\]. In terms of prognosis, TAMs were associated with worse overall survival in many solid tumors according to a large meta-analysis \[[@B255-cancers-11-00628]\]. In BC in particular, a meta-analysis of sixteen studies revealed that a high TAM density was associated with worse overall survival (Hazard Ratio \[HR\]=1.50; 95% Confidence Intervals \[CI\] 1.20-1.88) and disease-free survival (HR=2.22; 95% CI 1.71-2.89) \[[@B256-cancers-11-00628]\]. Overall, therapeutic strategies against TAMs are based on two major approaches: a) targeting TAM recruitment and activation, and b) reprogramming macrophage polarization towards an anti-tumoral phenotype. The first approach includes the elimination of TAM and monocyte accrual to the tumor site through the inhibition of mainly CSF-1/CSF-1R (Colony Stimulating Factor 1/ Colony Stimulating Factor 1 Receptor) and CCL2/CCR2 (C-C Motif Chemokine Ligand 2/ C-C Motif Chemokine Receptor 2) signaling axes. The second approach relies on the fact that TAMs are mostly of the M2-like phenotype and thus, stimulating the properties of the M1-like phenotype could be an effective treatment option to restore anti-tumoral activity. Such potential treatments for the macrophage polarization shift include CD40-agonists and/or TLR7 agonists. Whether the aforementioned therapeutic agents can be combined with other therapies which can target angiogenesis, increase phagocytic activity or enhance anti-tumor immunity is currently under investigation \[[@B257-cancers-11-00628],[@B258-cancers-11-00628]\]. Moreover, recognition and targeting of other pro-tumoral chemokines and cytokines \[[@B259-cancers-11-00628]\] or novel targets could broaden the therapeutic spectrum in cancer immunotherapy.

3.1. CSF-1/CSF-1R {#sec3dot1-cancers-11-00628}
-----------------

TAM recruitment is highly controlled by the interaction of the glycoprotein CSF-1 with its receptor CSF-1R, a member of type III receptor tyrosine kinase family. Binding of CSF-1 to CSF-1R leads to activation, recruitment and proliferation of TAMs \[[@B260-cancers-11-00628]\]. CSF-1R is normally expressed in various cell types but its expression in BC cells has been correlated to worse prognosis \[[@B261-cancers-11-00628],[@B262-cancers-11-00628],[@B263-cancers-11-00628],[@B264-cancers-11-00628]\] ([Table 3](#cancers-11-00628-t003){ref-type="table"}). Therapeutic targeting of this axis is under active investigation ([Table 4](#cancers-11-00628-t004){ref-type="table"}).

3.2. CCR2/CCL2 {#sec3dot2-cancers-11-00628}
--------------

The recruitment of circulating monocytes from the bone marrow into the TME is also mediated by the expression of the chemokine ligand CCL2. The binding to its receptor CCR2 leads to the differentiation of monocytes into TAMs and to the subsequent promotion of their pro-tumoral activity, tumor cell proliferation, angiogenesis and metastatic dissemination \[[@B265-cancers-11-00628],[@B266-cancers-11-00628]\]. Expression of these chemo-attractants has been linked to worse prognosis in BC patients \[[@B267-cancers-11-00628],[@B268-cancers-11-00628],[@B269-cancers-11-00628],[@B270-cancers-11-00628],[@B271-cancers-11-00628]\] ([Table 3](#cancers-11-00628-t003){ref-type="table"}). Targeting this axis using CCR2 antagonists and anti-CCL2 antibodies is currently being explored in advanced solid malignancies, including BC ([Table 4](#cancers-11-00628-t004){ref-type="table"}).

3.3. CD47 and SIRPa {#sec3dot3-cancers-11-00628}
-------------------

Interaction between the two cell-surface immunoglobulin family members, CD47 and signal regulatory protein alpha (SIRPα), is crucial for the regulation of phagocytosis. CD47 is expressed on cancer cells while SIRPα is expressed on macrophages. Upon interaction, the anti-tumor immunity is diminished as CD47 represents a 'don't eat me' signal, thus impairing phagocytosis \[[@B296-cancers-11-00628],[@B297-cancers-11-00628]\]. Through targeting this checkpoint axis using anti-CD47 antibodies, CD47-Fc and/or SIRPα-Fc fusion proteins, the macrophage phagocytic capacity can be restored (antibody-dependent cellular phagocytosis, ADCP) towards an effective immune response. The first reported efficacy results of the Hu5F9-G4 inhibitor combined with rituximab in non-Hodgkin's lymphoma are promising \[[@B298-cancers-11-00628]\]. Possible synergistic effects of such treatments with anti-HER2 or anti-PD-L1/PD-1 antibodies are being tested in clinical trials ([Table 4](#cancers-11-00628-t004){ref-type="table"}).

3.4. TLR7 {#sec3dot4-cancers-11-00628}
---------

TLR7 represents an intracellular receptor, member of the toll-like receptors transmembrane glycoprotein family. Its expression can enhance the DC function and can re-programme macrophages towards an anti-tumoral M1 phenotype \[[@B299-cancers-11-00628],[@B300-cancers-11-00628]\]. Therefore, its activation using TLR7 agonists could provide effective anti-tumor responses. Indeed, the use of the topical TLR7-agonist imiquimod in combination with nab-paclitaxel led to the short-term regression of BC cutaneous metastases in early phase trials \[[@B301-cancers-11-00628],[@B302-cancers-11-00628]\] ([Table 4](#cancers-11-00628-t004){ref-type="table"}).

3.5. CD40 {#sec3dot5-cancers-11-00628}
---------

CD40 represents a co-stimulatory protein, member of the TNF receptor family and is an emerging target in cancer immunotherapy. CD40 is mostly expressed by APC and macrophages and binding of its ligand (CD40L) on T-cells results in T-cell activation \[[@B303-cancers-11-00628]\]. Preclinical data of the CD40-agonist efficacy have been reported in BC and other tumor types, demonstrating the promotion of T-cell responses \[[@B304-cancers-11-00628],[@B305-cancers-11-00628]\]. CD40 activation using agonistic monoclonal antibodies can also lead to the enhancement of macrophage tumoricidal and pro-inflammatory properties mainly through MHC-II upregulation \[[@B303-cancers-11-00628]\]. Preliminary results indicate activity and durable immune responses \[[@B306-cancers-11-00628]\] ([Table 4](#cancers-11-00628-t004){ref-type="table"}).

4. Natural-Killer Cells and Related Markers {#sec4-cancers-11-00628}
===========================================

4.1. Killer Immunoglobin Receptors (KIR) {#sec4dot1-cancers-11-00628}
----------------------------------------

NK-cells represent an immune cell subpopulation with an active role in effective antitumor immunity \[[@B307-cancers-11-00628]\]. MHC class I specific Killer Immunoglobin Receptor (KIR) family members are mostly expressed on the surface of NK-cells. Some KIR - upon binding to their ligands HLA-B or HLA-C - can hinder NK cell activation \[[@B308-cancers-11-00628]\], while others are associated with NK stimulatory properties and better prognosis for cancer patients \[[@B309-cancers-11-00628],[@B310-cancers-11-00628]\]. Ongoing clinical trials are underway, testing antibodies against NK-inhibiting KIR family members in combination with other immune checkpoint inhibitors ([Table 4](#cancers-11-00628-t004){ref-type="table"}).

4.2. CD94/NKG2A {#sec4dot2-cancers-11-00628}
---------------

NK group member 2A (NKG2A) represents a novel inhibitory receptor, which forms heterodimers with CD94, both belonging to the C-type lectin-like family and expressed mainly on the surface of NK-cells and also on CD8+ T-cells. Upon binding of the complex to its MHC class I (HLA-E) ligand, the anti-tumoral capacity of NK-cells can be hindered and an immunosuppressive phenotype through T-cell inactivation is established \[[@B308-cancers-11-00628],[@B311-cancers-11-00628]\]. Recently, two preclinical studies in colorectal and head and neck carcinoma demonstrated that blockade of this receptor may be a new appealing immunotherapeutic target \[[@B312-cancers-11-00628],[@B313-cancers-11-00628]\]. Expression of NKG2A has been described in BC patients \[[@B273-cancers-11-00628]\], however no studies on therapeutic targeting are ongoing ([Table 3](#cancers-11-00628-t003){ref-type="table"}).

4.3. NK-Cell Activating Receptors {#sec4dot3-cancers-11-00628}
---------------------------------

NK-cells are activated through various receptors such as the natural cytotoxicity receptor (NCR) family (NCR1 or NKp46, NCR2 or NKp44, NCR3 or NKp30) and NK group member 2D (NKG2D). The latter recognizes several ligands including MHC class I polypeptide-related sequence (MICA/MICB) and UL16-binding proteins (ULBP1-6) and their interaction leads to enhanced cytolysis \[[@B314-cancers-11-00628],[@B315-cancers-11-00628]\]. Expression of NKG2D ligands has been associated with improved survival in BC \[[@B274-cancers-11-00628],[@B316-cancers-11-00628],[@B317-cancers-11-00628]\] ([Table 3](#cancers-11-00628-t003){ref-type="table"}).

5. IDO {#sec5-cancers-11-00628}
======

Indoleamine 2,3 dioxygenase-1 (IDO1) is an enzyme mostly found in DC and an appealing target for cancer immunotherapy \[[@B318-cancers-11-00628]\]. It plays an important role in metabolism-mediated immune regulation by catalyzing the conversion of amino acid tryptophan to kynurenine and thus impairing T-cell activation and promoting Treg expansion \[[@B319-cancers-11-00628],[@B320-cancers-11-00628]\]. IDO expression in BC patients has been extensively studied, with varying positivity, from 14 to 100% of the cases \[[@B276-cancers-11-00628],[@B279-cancers-11-00628]\]. Most of the studies describe a predominant expression by tumor cells with limited expression by stromal dendritic-like cells and occasional expression by myoepithelial cells. Although conflicting results have been reported, the majority of the studies show that the IDO expression is correlated to an advanced stage at diagnosis, high grade, ER negativity and worse outcome \[[@B277-cancers-11-00628],[@B278-cancers-11-00628]\]. Recent findings from a phase I trial, indicate the activity and safety of targeting IDO in combination with anti-PD-L1 monoclonal antibody atezolizumab in various advanced solid tumors including BC \[[@B321-cancers-11-00628]\].

6. Myeloid-Derived Suppressor Cells {#sec6-cancers-11-00628}
===================================

MDSCs represent a heterogeneous population of immature myeloid cells including progenitor cells, immature DCs, macrophages and granulocytes. In humans, MDSCs are defined by the positive expression of CD33 and CD11b and negative or reduced expression of HLA-DR. MDSCs are further classified as monocytic or granulocytic MDSCs when CD14 or CD15 is expressed, respectively.

MDSCs play a major role in promoting an immunosuppressive microenvironnment through various mechanisms: Production of reactive oxygen and nitrogen species depleting TILs \[[@B322-cancers-11-00628],[@B323-cancers-11-00628]\], impairment of lymphocyte-homing \[[@B324-cancers-11-00628]\], promotion of other immunosuppressive cells such as Tregs and M2-macrophages \[[@B325-cancers-11-00628],[@B326-cancers-11-00628]\], depletion of metabolites involved in the T cell function such as L-arginine and cysteine \[[@B327-cancers-11-00628],[@B328-cancers-11-00628]\] PD-L1 expression \[[@B329-cancers-11-00628]\] and adenosine production by upregulating the expression of ectonucleosidases CD39 and CD73 \[[@B330-cancers-11-00628]\]. In addition to their immunosuppressive effect, MDSCs also promote tumor dissemination and metastasis by affecting epithelial-mesenchymal transition \[[@B331-cancers-11-00628]\], degradation of extra-cellular matrix \[[@B332-cancers-11-00628]\], stem cell formation \[[@B333-cancers-11-00628]\], angiogenesis and formation of premetastatic niches \[[@B334-cancers-11-00628],[@B335-cancers-11-00628]\].

Presence of MDSCs in BC patients has been studied both in peripheral blood and primary tumors. Patients with BC have elevated levels of circulating MDSCs compared to healthy donors or patients with benign lesions and the levels of MDSCs increase with tumor burden (i.e. clinical stage), making it a potential tool for BC diagnosis \[[@B336-cancers-11-00628],[@B337-cancers-11-00628]\]. MDSCs are also present in the BC tumor microenvironment at significantly higher levels than the adjacent healthy breast tissue and one study found that TNBC seems to be more infiltrated than other BC subtypes \[[@B338-cancers-11-00628],[@B339-cancers-11-00628],[@B340-cancers-11-00628]\]. Moreover, MDSCs represent a potential biomarker for predicting both survival and response to NACT, with higher levels of circulating of infiltrating MDSCs being associated with worse survival and pCR rates \[[@B340-cancers-11-00628],[@B341-cancers-11-00628],[@B342-cancers-11-00628],[@B343-cancers-11-00628]\].

As a result, targeting MDSCs is a putative therapeutic tool for BC patients and different strategies have shown promising results in pre-clinical studies \[[@B344-cancers-11-00628],[@B345-cancers-11-00628],[@B346-cancers-11-00628],[@B347-cancers-11-00628]\]. Briefly, current treatment strategies aim to modulate myelopoïesis by forcing differentiation into mature cells or inhibiting maturation from precursor cells, block MDSC accumulation in tumor sites and block MDSC immunosuppressive functions \[[@B348-cancers-11-00628]\]. To our knowledge, only pre-clinical data of MDSC targeting in BC have been published but three early-phase clinical trials are currently ongoing (NCT03145012; NCT02922764; NCT02499328).

7. Implementing Combination Immunotherapy in the Clinic {#sec7-cancers-11-00628}
=======================================================

Blockade of the PD-1/PD-L1 axis through the use of monoclonal antibodies as monotherapies has met with considerable success during the past decade. The central concept of immunotherapy with the inhibition of negative regulators of the immune response is the restoration of activity of exhausted cytotoxic T-lymphocytes. As evidenced by the observation of responses among patients lacking a local immune response (no PD-1/PD-L1 expression at the protein level, absence of TIL), a pre-existing immune response is not an absolute prerequisite needed for the elicitation of responses to treatment. Nevertheless, response rates and response duration following treatment with a monotherapy seem to be lower among those patients \[[@B349-cancers-11-00628]\].

Intriguingly, the combined immune checkpoint blockade confers superior results compared to PD-1 blockade alone in this patient group. Data derived from the phase 3 CheckMate 067 trial indicate that double PD-1 and CTLA-4 blockade with nivolumab and ipilimumab improved both progression-free (HR=0.67; 95% CI were not reported) and overall survival (HR = 0.70) compared with nivolumab alone in patients with metastatic melanoma and PD-L1 expression lower than 1% \[[@B350-cancers-11-00628]\]. Although this analysis is exploratory and the trial was not designed to perform this comparison, it provides support for immunotherapy combinations. The theoretical background seems intuitive. Mechanistically the two checkpoints function on different sites of immune activation: CTLA-4 carries out its function at the sites of priming whereas PD-1 is responsible for maintaining tolerance by dampening the activation of T-lymphocytes in the periphery \[[@B351-cancers-11-00628]\]. It is unclear however whether the combinatory approach is successful thanks to an additive effect of the two inhibitors or if it results from the suppression of escape mechanisms. Similarly, it is conceivable that the inhibition of other negative regulators or agonistic activation of co-stimulatory molecules in combination with each other or with established immunotherapies can lead to further improvements in terms of patient outcomes. It is clear however that a mechanistic understanding of the biology of the candidate therapeutic targets and of the cross-talk that is activated upon inhibition is of paramount importance. Further underscoring the need for a deep understanding of the underlying biologic processes and the rational design of novel agents is the failure of the combination of the once promising IDO1 inhibitor epacadostat to improve outcomes in combination with pembrolizumab versus pembrolizumab alone in patients with metastatic melanoma \[[@B352-cancers-11-00628]\].

While increased efficacy is the main goal, two barriers need to be overcome for successful integration of novel immunotherapies: Toxicity and financial cost. The clinical use of the checkpoint inhibition is associated with a risk for serious, potentially fatal immune-related adverse events (irAEs). Following this paradigm, the ability to inhibit multiple targets simultaneously may be limited by the adverse event profile of such combinations. It is important to note that while it is unclear whether the same molecular mechanisms that drive tumor rejection are to blame for the induction of irAEs, both retrospective \[[@B353-cancers-11-00628]\] and limited prospective data \[[@B354-cancers-11-00628]\] show a correlation between irAEs and better outcomes. This correlation has not been adequately studied if it also concerns combinatorial immunotherapy, which is associated with a higher risk for severe irAEs according to the aforementioned CheckMate 067 trial \[[@B350-cancers-11-00628]\].

On the other hand, the revolution of cancer immunotherapy has brought to the limelight the associated financial costs. Published data indicate that the combination of nivolumab and ipilimumab, despite its efficacy, is not a cost-effective option \[[@B355-cancers-11-00628]\]. How quickly and widely the combination will be adopted in light of the positive results from randomized trials on malignancies that can be readily treated with other options \[[@B356-cancers-11-00628],[@B357-cancers-11-00628]\], remains to be seen. It is reasonable to assume that future combinations with novel agents will not differ in that respect. In addition, the evaluation of novel combinations will likely be plagued by the same problems that have affected PD-1/PD-L1 inhibitors: Inconclusive predictive biomarkers lacking analytical validity and clinical validity/utility, variety of companion diagnostics using different antibodies and cut-offs, trials reporting different results from different antibodies in the same clinical setting and overabundance of available options with no hints on their differential efficacy \[[@B7-cancers-11-00628]\]. It is therefore imperative that future phase 3 trials will be based on robust preclinical and early clinical data.

8. Conclusions {#sec8-cancers-11-00628}
==============

A large number of co-stimulatory or co-inhibitory molecules regulating tumor evasion from immunosurveillance have been studied in BC ([Table 5](#cancers-11-00628-t005){ref-type="table"}). As reviewed here, there are solid pre-clinical data on the function of these factors and emerging data on their regulation and their role in the clinical setting. These molecules likely represent future targets of immunotherapy provided that the promise shown in early data is translated into improved patient survival in randomized trials.

While it seems counterintuitive that the development of the next generation of immunotherapy agents precedes the optimization of the currently available ones, early recognition of the most promising agents can hasten their implementation in clinical practice. As we previously characterized the emergence of the PD-1/PD-L1 inhibition as the "end of the beginning" of cancer immunotherapy \[[@B7-cancers-11-00628]\], the exciting advances that are described in this review could very well represent the "beginning of the end" of non-selective cytotoxic chemotherapy.
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cancers-11-00628-t001_Table 1

###### 

Expression and prognostic/predictive value of immune-related markers predominantly expressed on T-cells.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Marker                 BC\                               Number of Patients        Method                                                                                                                     Positive/\                                                                                                                                 Prognostic/Predictive Value                                                                                                           Comments                                                                              Reference
                         Subtype                                                                                                                                                                                Overexpressing Cases                                                                                                                                                                                                                                                                                                                                                   
  ---------------------- --------------------------------- ------------------------- -------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------- -----------------------------
  **LAG-3**              All                               8                         RT-PCR                                                                                                                     LAG-3 expression: 8/8 (100%)                                                                                                               NA                                                                                                                                    LAG-3 overexpression in BC compared to adjacent healthy tissue                        \[[@B23-cancers-11-00628]\]

  All                    148 pre-NACT\                     IHC                       LAG-3 positivity:\                                                                                                         LAG-3 expression: pedictive for pCR in UA but not MA                                                                                       Positive case cut-off: expression ≥ 5%                                                                                                \[[@B28-cancers-11-00628]\]                                                           
                         114 post-NACT                                               Pre-NACT: 33/148 (22.3%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                                     Post-NACT: 38/114 (33.3%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  TNBC                   259 (training set)\               IHC                       LAG-3 positivity: 65/363 (18%)                                                                                             LAG-3 positivity: trend to better RFS and OS in UA                                                                                         Positive case cut-off: expression ≥ 5%                                                                                                \[[@B25-cancers-11-00628]\]                                                           
                         104 (validation set)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  All                    330 (training set)\               IHC                       LAG-3 positivity:\                                                                                                         LAG-3 positivity: better BCSS and RFS in MA but not when considering CD8, PD-1 and PD-L1                                                   Positive case cut-off: ≥ 1 TILs per TMA core\                                                                                         \[[@B26-cancers-11-00628]\]                                                           
                         3992 (validation set)                                       327/2921 (11%)                                                                                                                                                                                                                                                        2921 evaluable in validation set                                                                                                                                                                                            

  **TIM-3**              All                               150                       IHC                                                                                                                        BC cases:\                                                                                                                                 NA                                                                                                                                                                                                                          \[[@B29-cancers-11-00628]\]
                                                                                                                                                                                                                TIM-3 + tumor cells 147/150 (98%)\                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                TIM-3+CD8+ T cells 135/150 (90%)Healthy controls:\                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                TIM-3+ epithelial cells 13/100 (13%)\                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                TIM-3+CD8+ T-cells 23/100 (23%)                                                                                                                                                                                                                                                                                                                                        

  All                    20                                FC                        NA                                                                                                                         NA                                                                                                                                         Peripheral blood: overexpression of TIM-3 in CD4+CXCR5+ICOS+ T cells compared to healthy controls\                                    \[[@B30-cancers-11-00628]\]                                                           
                                                                                                                                                                                                                                                                                                                                                           TILs: overexpression of TIM-3 in CD4+CXCR5+ICOS+ T cells compared to peripheral blood of same patients                                                                                                                      

  All                    8                                 RT-PCR                    TIM-3 expression: 8/8 (100%)                                                                                               NA                                                                                                                                         Overexpression in BC compared to healthy adjacent tissue                                                                              \[[@B23-cancers-11-00628]\]                                                           

  All                    3169                              Gene expression dataset   No overexpression                                                                                                          NA                                                                                                                                         Use of gene expression dataset *Genevestigator v3*                                                                                    \[[@B31-cancers-11-00628]\]                                                           

  All                    3992\                             IHC                       TIM-3+ iTILs: 332/3148 (11%)\                                                                                              TIM-3+ iTILs: better BCSS\                                                                                                                 TIM-3 iTILs cut-off: expression ≥ 1 iTIL\                                                                                             \[[@B32-cancers-11-00628]\]                                                           
                         (3148 evaluable)                                            TIM-3+ sTILs: 630/3148                                                                                                     TIM-3+ sTILs: statistically not significant better BCSS                                                                                    TIM-3 sTILs cut-off: expression ≥ 2 sTILs\                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                           TIM-3+ iTILs correlated to basal-like subtype                                                                                                                                                                               

  **VISTA**              NA                                NA                        NA                                                                                                                         NA                                                                                                                                         NA                                                                                                                                    NA                                                                                    NA

  **TIGIT**              All                               3169                      Gene expression dataset                                                                                                    TIGIT overexpression in 72%                                                                                                                NA                                                                                                                                    Use of gene expression dataset *Genevestigator v3*                                    \[[@B31-cancers-11-00628]\]

  TNBC                   47                                Gene expression dataset   NA                                                                                                                         TIGIT overexpression: better RFS and OS                                                                                                    Use of gene expression dataset from GEO datasets (GDS2250 and GSE3744)                                                                \[[@B33-cancers-11-00628]\]                                                           

  All                    8                                 RT-PCR                    TIGIT expression: 8/8 (100%)                                                                                               NA                                                                                                                                         No overexpression of TIGIT in BC compared to adjacent healthy tissue                                                                  \[[@B23-cancers-11-00628]\]                                                           

  **GITR**               All                               33                        FC                                                                                                                         NA                                                                                                                                         NA                                                                                                                                    PT Tregs: 80.5% expression of GITR\                                                   \[[@B34-cancers-11-00628]\]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Circulating Tregs: 28.9% expression of GITR                                           

  All                    39                                FC                        NA                                                                                                                         NA                                                                                                                                         PT CD4+h T cells: higher GITR expression than healthy control CD4+ T cells                                                            \[[@B35-cancers-11-00628]\]                                                           

  All                    3169                              Gene expression dataset   GITR overexpression in 42%                                                                                                 NA                                                                                                                                         Use of gene expression dataset *Genevestigator v3*                                                                                    \[[@B31-cancers-11-00628]\]                                                           

  Not specified          3                                 FC                        NA                                                                                                                         NA                                                                                                                                                                                                                                                                               \[[@B36-cancers-11-00628]\]                                                           

  Not specified          17                                FC                        NA                                                                                                                         NA                                                                                                                                         More T regs expressing GITR in BC patients than healthy donors (*n* = 10)                                                             \[[@B37-cancers-11-00628]\]                                                           

  **B7-H3**              All                               221                       IHC                                                                                                                        B7-H3 high expression:\                                                                                                                    NA                                                                                                                                                                                                                          \[[@B38-cancers-11-00628]\]
                                                                                                                                                                                                                Healthy controls: 14/85 (16.48%)\                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                BC: 178/221 (80.55%)                                                                                                                                                                                                                                                                                                                                                   

  All                    82                                RT-PCR                    B7-H3 overexpression: 32/82 (39%)                                                                                          NA                                                                                                                                                                                                                                                                               \[[@B39-cancers-11-00628]\]                                                           

  All                    117                               IHC                       B7-H3 positivity: 106/117 (90.6%)                                                                                          NA                                                                                                                                         Positive case cut-off: expression \> 10%                                                                                              \[[@B40-cancers-11-00628]\]                                                           

  All                    90                                IHC                       B7-H3 high: 83/90 (92%)                                                                                                    B7-H3 high: worse RFS but no association with OS                                                                                                                                                                                                                                 \[[@B41-cancers-11-00628]\]                                                           

  All                    74                                IHC                       B7-H3 IHC positivity:\                                                                                                     B7-H3 positivity: worse OS                                                                                                                                                                                                                                                       \[[@B42-cancers-11-00628]\]                                                           
                                                                                     BC 42/74 (56.8%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                     healthy controls 32/74 (43.2%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  All                    97                                IHC                       NA                                                                                                                         NA                                                                                                                                         B7-H3 expression significantly higher in BC (*n*=97) compared to normal tissue (*n* = 53), benign, and precursor lesion (*n* = 182)   \[[@B43-cancers-11-00628]\]                                                           

  All                    208                               IHC                       B7-H3 positivity:\                                                                                                         NA                                                                                                                                                                                                                                                                               \[[@B44-cancers-11-00628]\]                                                           
                                                                                     BC: 154/208 (74%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
                                                                                     Healthy controls: 3/7 (43%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  All                    101                               IHC                       B7-H3 positivity:\                                                                                                         NA                                                                                                                                                                                                                                                                               \[[@B45-cancers-11-00628]\]                                                           
                                                                                     BC: 88/101 (88%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                     Healthy controls: 6/47 (12.8%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  **ICOS**               All                               120                       IHC\                                                                                                                       NA                                                                                                                                         ICOS positivity:\                                                                                                                     Positive case cut-off: expression ≥1.7 positive cells\                                \[[@B46-cancers-11-00628]\]
                                                                                     FC                                                                                                                                                                                                                                                                    UA: worse PFS and OS\                                                                                                                 Tumoral Treg ICOS+: 69.9%\                                                            
                                                                                                                                                                                                                                                                                                                                                           MA: not significant                                                                                                                   BC circulating Treg ICOS+: 16.6%\                                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Healthy circulating Treg ICOS+: 21.3%                                                 

  **4-1BB**              All                               3169                      Gene expression dataset                                                                                                    4-1BB overexpression in 42%                                                                                                                NA                                                                                                                                    Use of gene expression dataset *Genevestigator v3*                                    \[[@B31-cancers-11-00628]\]

  All                    286                               Gene expression dataset   NA                                                                                                                         4-1BB expression: better DFMS                                                                                                                                                                                                                                                    \[[@B47-cancers-11-00628]\]                                                           

  Not specified          4                                 IHC                       4-1BB positivity: 2/4 (50%)                                                                                                NA                                                                                                                                         Positive case cut-off: expression \> 10%                                                                                              \[[@B48-cancers-11-00628]\]                                                           

  **CD70**               All                               204                       IHC                                                                                                                        CD70 positivity: 5/204 (2.45%)                                                                                                             NA                                                                                                                                                                                                                          \[[@B49-cancers-11-00628]\]

  All                    139 (110/139 with metastasis)\    IHC                       CD70 expression: 81/139 (58.3%)                                                                                            CD70 expression: worse lung MFS                                                                                                                                                                                                                                                  \[[@B50-cancers-11-00628]\]                                                           
                         233 (stage I -- III)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  All                    16 (pre and post-NACT)            RT-PCR                    NA                                                                                                                         CD70 overexpression after NACT: better PFS                                                                                                                                                                                                                                       \[[@B51-cancers-11-00628]\]                                                           

  **OX40 and OX40L**     All                               107\                      IHC                                                                                                                        Positivity in PT:\                                                                                                                         NA                                                                                                                                    Positive case cut-off: expression on \> 10% tumor cells\                              \[[@B52-cancers-11-00628]\]
                                                           9 DICS                                                                                                                                               OX40 91/107 (85%)\                                                                                                                                                                                                                                                               OX40 associated with advanced stage                                                   
                                                                                                                                                                                                                OX40L 89/107 (83.2%)\                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                Positivity in DCIS:\                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                OX40 6/9 (66.7%)\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                OX40L 7/9 (77.8%)                                                                                                                                                                                                                                                                                                                                                      

  Not specified          19                                IHC                       OX40 positivity: 10/19 (52.6%)                                                                                             NA                                                                                                                                         Positive case cut-off: expression on \> 10% cells                                                                                     \[[@B53-cancers-11-00628]\]                                                           

  Not specified          Not specified                     IHC\                      OX40+CD4+ TILs in 43% of the BC cases                                                                                      NA                                                                                                                                         No OX40 expression on circulation CD4 T cells                                                                                         \[[@B54-cancers-11-00628]\]                                                           
                                                           FC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Not specified          45                                IHC                       OX40 positivity: 7/45 (15.55%)                                                                                                                                                                                                                                        OX40 expressed on TILs\                                                                                                               \[[@B55-cancers-11-00628]\]                                                           
                                                                                                                                                                                                                                                                                                                                                           OX40 expression also found on positive LN                                                                                                                                                                                   

  Not specified          44                                IHC                       OX40 positivity: 7/18 (30%) of theCD4+ cases                                                                               NA                                                                                                                                                                                                                                                                               \[[@B56-cancers-11-00628]\]                                                           

  **BTLA**               All                               3080                      Gene-expression dataset                                                                                                    BTLA overexpressed in TNBC compared to non-TNBC                                                                                            BTLA overexpression in TNBC: better OS and DFS                                                                                        Use of gene expression profiles of breast invasive carcinoma from TCGA and METABRIC   \[[@B57-cancers-11-00628]\]

  All                    660                               IHC\                      BTLA positivity: 15/660 (2.3%)                                                                                             NA                                                                                                                                         Positive case cut-off: ≥ 1 BTLA+ TIL\                                                                                                 \[[@B58-cancers-11-00628]\]                                                           
                                                           FC                                                                                                                                                                                                                                                                                              All BTLA+ TILs also expressed PD-1\                                                                                                                                                                                         
                                                                                                                                                                                                                                                                                                                                                           According to FC, CD4 and CD8+TILs don't express BTLA                                                                                                                                                                        

  **TLR9**               TNBC (Afro-American population)   51                        IHC                                                                                                                        TLR9 "low" expression: 27/51 (52.9%)\                                                                                                      TLR9 high: no association with recurrence or BCSS                                                                                     Variants of TLR9 gene associated with protection from breast cancer                   \[[@B59-cancers-11-00628]\]
                                                                                                                                                                                                                TLR9 "high" expression: 22/51 (43.1%)                                                                                                                                                                                                                                                                                                                                  

  All and TNBC           84 of all subtypes\               RT- PCRIHC                mRNA expression in cohort of 84 cases of all subtypes: overexpression in TNBC\                                             High mRNA expression: trend to better MFS\                                                                                                 TLR9 also expressed in pre-invasive lesions                                                                                           \[[@B60-cancers-11-00628]\]                                                           
                         80 TNBC\                                                    IHC expression in sub-group analyses of 38/84 cases of all subtypes: overexpression in 8/38 (21%) and 5/13 (38.5%) TNBC\   High protein expression in 80 TNBC: better MFS                                                                                                                                                                                                                                                                                                                         
                         350 of all subtypes                                         IHC expression in 80 TNBC cases: 32/80 (40%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                     mRNA expression in 350 cases of all subtypes: overexpression in 50/350 (14.3%) and 19/64 (29.7%) TNBC                                                                                                                                                                                                                                                                                                                                                                                             

  All                    196                               IHC                       TLR9 high expression in TNBC: 51/99 (51.5%)                                                                                TLR9 high expression: All subtypes: no association foundTNBC: high expression better BCSS                                                                                                                                                                                        \[[@B61-cancers-11-00628]\]                                                           

  All                    12                                RT-PCR                    TLR9 expression: 12/12 (100%)                                                                                              NA                                                                                                                                                                                                                                                                               \[[@B62-cancers-11-00628]\]                                                           

  All                    124                               IHC                       TLR9 positivity: 78/124 (63%)                                                                                              TLR9 positivity: UA: worse PFSMA: not statistically significant                                                                            Positive case cut-off: expression \> 10% cells\                                                                                       \[[@B63-cancers-11-00628]\]                                                           
                                                                                                                                                                                                                                                                                                                                                           Expression significantly higher in tumors with positive axillary LN metastasis, ER- and advanced stage                                                                                                                      

  All                    74                                IHC                       TLR9 expression:\                                                                                                          TLR9 positive expression by fibroblasts: better DMFS                                                                                                                                                                                                                             \[[@B64-cancers-11-00628]\]                                                           
                                                                                     By tumor cells: 73/74 (98.6%)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                                     By fibroblasts 42/74 (58%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  All                    124\                              RT-PCR\                   TLR9 mRNA: overexpression in ER-\                                                                                                                                                                                                                                     IHC expression higher in ER and PR-                                                                                                   \[[@B65-cancers-11-00628]\]                                                           
                         116 post-menopausal               IHC                       TLR9 IHC expression in 116 post-menopausal: 103/116 (88.8%)                                                                                                                                                                                                                                                                                                                                                                                                                                       

  All                    141                               IHC                       TLR9 positivity: 136/141 (98%)                                                                                             TLR9 positivity: worse DMFS                                                                                                                Higher expression in ER- and high grade tumors                                                                                        \[[@B66-cancers-11-00628]\]                                                           

  **A2aR**               NA                                NA                        NA                                                                                                                         NA                                                                                                                                         NA                                                                                                                                    NA                                                                                    NA

  **CD73**               All                               80                        IHC                                                                                                                        NA                                                                                                                                         CD73 expresion in ER+ cases: no prognostic value\                                                                                     CD73 expression associated with EGFR expression                                       \[[@B67-cancers-11-00628]\]
                                                                                                                                                                                                                                                                                                                                                           CD73 expression in ER- cases: worse OS                                                                                                                                                                                      

  All                    136                               IHC                       CD73 positivity: 101/136 (74%)                                                                                             CD73 positivity:\                                                                                                                                                                                                                                                                \[[@B68-cancers-11-00628]\]                                                           
                                                                                                                                                                                                                UA: better DFS and OS\                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                MA: better DFS, trend to better OS                                                                                                                                                                                                                                                                                                                                     

  All (Her2 status NA)   102                               IHC                       CD73 positivity: 9/102 (9%)                                                                                                NA                                                                                                                                         Positive case cut-off: any expression by tumor cells                                                                                  \[[@B69-cancers-11-00628]\]                                                           

  Not specified          74                                IHC                       CD73 positivity: 60/74 (81%)                                                                                               NA                                                                                                                                         Positive case cut-off: expression \>5% cells                                                                                          \[[@B70-cancers-11-00628]\]                                                           

  TNBC                   122                               IF                        NA                                                                                                                         Tumor cells CD73 expression: UA: worse DFS and OSMA: worse DFS, trend to worse OSStromal and immune CD73 expression: no prognostic value                                                                                                                                         \[[@B71-cancers-11-00628]\]                                                           

  All                    119                               IHC                       CD73 positivity: 100/119 (84%)                                                                                             NA                                                                                                                                                                                                                                                                               \[[@B72-cancers-11-00628]\]                                                           

  All                    202                               Gene expression dataset   NA                                                                                                                         Gene-expression database of 1128 cases of all subtypes: worse DFS\                                                                                                                                                                                                               \[[@B73-cancers-11-00628]\]                                                           
                                                                                                                                                                                                                Gene-expression of 417 Her2+ cases: worse DFS\                                                                                                                                                                                                                                                                                                                         
                                                                                                                                                                                                                Gene-expression of 784 ER+ and 211 TNBC cases: statistically NS trend to worse DFS\                                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                METABRIC cohort of 1981 cases of all subtypes: worse DSS                                                                                                                                                                                                                                                                                                               

  All and TNBC           6209 all subtypes\                Gene expression dataset   NA                                                                                                                         6209 cases of all subtypes: worse OS for TNBC, no prognostic value for ER+ and Her2+ cases\                                                                                                                                                                                      \[[@B74-cancers-11-00628]\]                                                           
                         59 TNBC                                                                                                                                                                                59 TNBC: worse response to NACT                                                                                                                                                                                                                                                                                                                                        

  **CD39**               Not specified                     33                        FC                                                                                                                         PT CD39+CD8+ TILs mean frequency: 18.5% +/− 4.3%\                                                                                          NA                                                                                                                                                                                                                          \[[@B75-cancers-11-00628]\]
                                                                                                                                                                                                                Circulating CD8+ T cells: no CD39 expression                                                                                                                                                                                                                                                                                                                           

  All (Her2 NA)          11                                FC                        NA                                                                                                                         NA                                                                                                                                         CD39+CD4+ TILs 28.7+/−5.8% vs 8.2+/−5.9% in normal adjacent tissue\                                                                   \[[@B76-cancers-11-00628]\]                                                           
                                                                                                                                                                                                                                                                                                                                                           CD39+CD8+ TILs 9+/−3.5% vs 0.4+/−0.3% in normal adjacent tissue                                                                                                                                                             

  All                    50                                FC\                       NA                                                                                                                         NA                                                                                                                                         CD39 +Th17 TILs 93.6%\                                                                                                                \[[@B77-cancers-11-00628]\]                                                           
                                                           IF\                                                                                                                                                                                                                                                                                             CD39 + TILs Tregs 50.9%\                                                                                                                                                                                                    
                                                           RT-PCR                                                                                                                                                                                                                                                                                          CD39 overexpressed among IL-17^Hi^ tumors                                                                                                                                                                                   

  All                    3169                              Gene expression dataset   No CD39 overexpression                                                                                                     NA                                                                                                                                         Use of gene expression dataset *Genevestigator v3*                                                                                    \[[@B31-cancers-11-00628]\]                                                           

  Not specified          10                                Gene expression dataset   CD39 overexpressed in BC compared to healthy tissue                                                                        NA                                                                                                                                         Micro-array dataset from *Turashvili et al.* (BMC Cancer. 2007 Mar 27;7:55.)                                                          \[[@B78-cancers-11-00628]\]                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** LAG-3, lymphocyte-activation gene 3; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; VISTA, V-domain Ig suppressor of T cell activation; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; GITR, glucocorticoid-induced TNFR-related protein; B7-H3, B7 homolog 3; ICOS, Inducible T-cell costimulator; 4-1BB; CD70, cluster of differentiation 70; BTLA, B- and T-lymphocyte attenuator; TLR9, Toll-like receptor 9; A2aR, A2A adenosine receptor; CD73, cluster of differentiation 73; CD39, cluster of differentiation 39; BC, breast cancer; TNBC, triple-negative breast cancer; Her2, human epidermal growth factor receptor 2; NACT, neo-adjuvant chemotherapy; RT-PCR, reverse transcription polymerase chain reaction; IHC, immunohistochemistry; FC, flow-cytometry; IF, immunofluorescence; mRNA, messenger RNA; TILs, tumor-infiltrating lymphocytes; NA, not assessed; UA, univariate analysis; MA, multivariate analysis; pCR, pathological complete response; RFS, relapse-free survival; OS, overall survival; BCSS, breast cancer specific survival; PD-1, Programmed cell death 1; PD-L1, Programmed death-ligand 1; DFMS, distant-metastasis free survival; MFS, metastasis-free survival; PFS, progression-free survival; DFS, disease-free survival; ER, estrogen receptor; PR, progesterone receptor; NS, non significant; DSS, disease-specific survival; TMA, tissue microarray; Tregs, regulatory T cells; LN, lymph-node; TCGA, the cancer genome atlas; EGFR, epidermal growth factor receptor.

cancers-11-00628-t002_Table 2

###### 

Ongoing clinical trials potentially including breast cancer patients for targeting immune-related markers predominantly expressed on T-cells.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target                                                                                                         Drug                                                     Other Agent(s)                                                                     Phase                                                                  Disease                                                            Line                                                                          NCT Identifier                                                          Trial Status
  -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------
  LAG-3                                                                                                          IMP 321\                                                 \+ Paclitaxel                                                                      I/II                                                                   Advanced BC                                                        1st line                                                                      NCT00349934                                                             Completed, published results\
                                                                                                                 (Eftilagimod)                                                                                                                                                                                                                                                                                                                                                                                                                               \[[@B27-cancers-11-00628]\]

  \+ Paclitaxel                                                                                                  Iib                                                      Hormone positive advanced BC                                                       1st line                                                               NCT02614833                                                        Recruiting, safety results published \[[@B79-cancers-11-00628]\]                                                                                      

  \+ Paclitaxel                                                                                                  I                                                        Advanced BC (chinese population)                                                   1st line                                                               NCT03600090                                                        Not yet recruiting                                                                                                                                    

  \+ standard therapy                                                                                            I                                                        Advanced solid tumors                                                              Any line                                                               NCT03252938                                                        Recruiting                                                                                                                                            

  MK-4280                                                                                                        +/− Pembrolizumab (anti-PD1)                             I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT02720068                                                                   Recruiting                                                              

  BMS-986016\                                                                                                    +/− Nivolumab (anti-PD1)                                 I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT02966548                                                                   Recruiting                                                              
  (Relatlimab)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  \+ Nivolumab (anti-PD1) and BMS-986205 (IDO1 inhibitor)\                                                       I/II                                                     Advanced solid tumors                                                              Any line                                                               NCT03459222                                                        Recruiting                                                                                                                                            
  Or + Nivolumab (anti-PD1) and Ipilimumab (anti-CTLA4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  REGN3767                                                                                                       +/− REGN2810 (anti-PD1)                                  I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT03005782                                                                   Recruiting                                                              

  LAG525\                                                                                                        +/− PDR001 (anti-PD1)                                    I/II                                                                               Advanced solid tumors including TNBC                                   ≥ 1 line                                                           NCT02460224                                                                   Active, not recruiting\                                                 
  (IMP701)                                                                                                                                                                                                                                                                                                                                                                                                                                                                           Preliminary results published \[[@B80-cancers-11-00628]\]               

  +/− PDR001 (anti-PD1)\                                                                                         II                                                       Advanced TNBC                                                                      1^st^ or 2^nd^ line                                                    NCT03499899                                                        Suspended                                                                                                                                             
  +/− Carboplatin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  \+ PDR001 (anti-PD1)\                                                                                          I/Ib                                                     TNBC                                                                               ≤ 2 lines                                                              NCT03742349                                                        Recruiting                                                                                                                                            
  + NIR178 (A2aR antagonist) or Capmantinib (C-MET inhibitor) or MCS110 (anti-M-CSF) or Canakinumab (anti-IL1)                                                                                                                                                                                                                                                                                                                                                                                                                                               

  TSR-033                                                                                                        \+ anti-PD1                                              I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT03250832                                                                   Recruiting                                                              

  INCAGN02385                                                                                                    No                                                       I                                                                                  Advanced solid tumors including TNBC                                   No standard therapy available                                      NCT03538028                                                                   Not yet recruiting                                                      

  Sym022                                                                                                         No                                                       I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT03489369                                                                   Recruiting                                                              

  \+ Sym021 (anti-PD1) or Sym023 (anti-TIM3)                                                                     I                                                        Advanced solid tumors                                                              No standard therapy available                                          NCT03311412                                                        Recruiting                                                                                                                                            

  MGD013 (Anti-\                                                                                                 No                                                       I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT03219268                                                                   Recruiting                                                              
  LAG3 + Anti-PD1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  FS118 (Anti-LAG3 + Anti-PDL1)                                                                                  No                                                       I                                                                                  Advanced solid tumors that progressed on anti-PD1/PDL-1 therapy        ≥ 1 line                                                           NCT03440437                                                                   Recruiting                                                              

  XmAb®22841 (Anti-\                                                                                             No                                                       I                                                                                  Advanced solid tumors including TNBC                                   No standard therapy available                                      NCT03849469                                                                   Not yet recruiting                                                      
  LAG3 + Anti-CTLA4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  TIM-3                                                                                                          MBG453                                                   +/− PDR001 (anti-PD1)                                                              I-Ib/II                                                                Advanced solid tumors (phase I)                                    No standard therapy available                                                 NCT02608268                                                             Recruiting

  TSR-022                                                                                                        No                                                       I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT02817633                                                                   Recruiting                                                              

  \+ Carboplatin\                                                                                                I                                                        Advanced solid tumors                                                              ≤ 1 line (part B)\                                                     NCT03307785                                                        Recruiting                                                                                                                                            
  + Nab-paclitaxel\                                                                                                                                                                                                                                          ≤ 4 lines (part A)\                                                                                                                                                                                                                                                                             
  + TSR-042 (anti-PD1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  LY3321367                                                                                                      +/− LY3300054 (anti-PDL1)                                Ia/Ib                                                                              Advanced solid tumors                                                  No standard therapy available                                      NCT03099109                                                                   Recruiting                                                              

  INCAGN02390                                                                                                    No                                                       I                                                                                  Advanced solid tumors including TNBC                                   No standard therapy availaible                                     NCT03652077                                                                   Recruiting                                                              

  Sym023                                                                                                         No                                                       I                                                                                  Advanced solid tumors                                                  No standard therapy availaible                                     NCT03489343                                                                   Recruiting                                                              

  \+ Sym021 (anti-PD1) or Sym022 (anti-LAG3)                                                                     I                                                        Advanced solid tumors                                                              No standard therapy available                                          NCT03311412                                                        Recruiting                                                                                                                                            

  LY3321367                                                                                                      +/− LY3300054 (anti-PDL1)                                I                                                                                  Advanced solid tumors                                                  Any line                                                           NCT03099109                                                                   Recruiting                                                              

  BGB-A425                                                                                                       +/− Tislelizumab (anti-PD1) for phase II                 I/II                                                                               Advanced solid tumors                                                  No standard therapy available                                      NCT03744468                                                                   Recruiting                                                              

  LY3415244 (Anti-TIM3 + Anti-PDL1)                                                                              No                                                       Ia/Ib                                                                              Advanced solid tumors                                                  Any line (phase Ia)\                                               NCT03752177                                                                   Recruiting                                                              
                                                                                                                                                                                                                                                                                                                                    ≥ 1 line with anti-PD1 or anti-PDL1 therapy (phase Ib)                                                                                                                                                                   

  MBG453                                                                                                         \+ PDR001 (anti-PD1)                                     I/II                                                                               Advanced solid tumors                                                  No standard therapy available and no prior anti-PD1/PDL1 therapy   NCT02608268                                                                   Recruiting                                                              

  VISTA                                                                                                          CA-170                                                   No                                                                                 I                                                                      Advanced solid tumors including TNBC                               No standard therapy availaible                                                NCT02812875                                                             Recruiting

  TIGIT                                                                                                          AB154                                                    +/− AB122 (anti-PD1)                                                               I                                                                      Advanced solid tumors                                              No standard therapy availaible                                                NCT03628677                                                             Recruiting

  OMP-313M32\                                                                                                    +/− Nivolumab (anti-PD1)                                 Ia/Ib                                                                              Advanced solid tumors                                                  No standard therapy availaible                                     NCT03119428                                                                   Active, not recruiting                                                  
  (Etigilimab)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                 BMS-986207                                               +/− Nivolumab (anti-PD1)                                                           I/II                                                                   Advanced solid tumors                                              No standard therapy availaible                                                NCT02913313                                                             Recruiting

  GITR                                                                                                           MK-4166                                                  +/− Pembrolizumab (anti-PD1)                                                       I                                                                      Advanced solid tumors                                              No standard therapy availaible                                                NCT02132754                                                             Active, not recruiting

  INCAGN01876                                                                                                    +/− Epacadostat (IDO1 inhibitor)\                        I/II                                                                               Advanced solid tumors (phase I)                                        No standard therapy availaible                                     NCT03277352                                                                   Active, not recruiting                                                  
                                                                                                                 +/− Pembrolizumab (anti-PD1)                                                                                                                                                                                                                                                                                                                                                                                                                

  +/− Nivolumab (anti-PD1)\                                                                                      I/II                                                     Advanced solid tumors (phase I)                                                    No standard therapy availaible                                         NCT03126110                                                        Recruiting                                                                                                                                            
  +/− Ipilimumab (anti-CTLA4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  No                                                                                                             I/II                                                     Advanced solid tumors (phase I)                                                    No standard therapy availaible                                         NCT02697591                                                        Recuiting                                                                                                                                             

  TRX518                                                                                                         +/− Gemcitabine\                                         I                                                                                  Advanced solid tumors (monotherapy and association with Gemcitabine)   No standard therapy availaible or indication for Gemcitabine       NCT02628574                                                                   Recruiting                                                              
                                                                                                                 +/− Pembrolizumab (anti-PD1)\                                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                 +/− Nivolumab (anti-PD1)                                                                                                                                                                                                                                                                                                                                                                                                                    

  No                                                                                                             I                                                        Advanced solid tumors                                                              No standard therapy availaible                                         NCT01239134                                                        Recruiting, safety results published \[[@B81-cancers-11-00628]\]                                                                                      

  \+ Cyclophosphamide and/or Avelumab (anti-PDL1)                                                                I/II                                                     Advanced solid tumors including TNBC and hormone receptor positive refractory BC   TNBC: 2nd or 3rd line\                                                 NCT03861403                                                        Not yet recruiting                                                                                                                                    
                                                                                                                                                                                                                                                             Hormone receptor positive BC: ≥ 1 line with aromatase inhibitor                                                                                                                                                                                                                                 

  BMS-986156                                                                                                     +/− Nivolumab (anti-PD1)                                 I/Iia                                                                              Advanced solid tumors                                                  No standard therapy availaible                                     NCT02598960                                                                   Active, not recruiting\                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     preliminary results \[[@B82-cancers-11-00628]\]                         

  +/− Nivolumab (anti-PD1)                                                                                       I                                                        Advanced solid tumors                                                              ≥ 2 lines                                                              NCT03335540                                                        Recruiting                                                                                                                                            

  GWN323                                                                                                         +/− PDR001 (anti-PD1)                                    I/Ib                                                                               Advanced solid tumors                                                  Not specified                                                      NCT02740270                                                                   Active, not recruiting                                                  

  MEDI1873                                                                                                       No                                                       I                                                                                  Advanced solid tumors                                                  Not specified                                                      NCT02583165                                                                   Completed, no published results                                         

  OMP-336B11                                                                                                     No                                                       Ia                                                                                 Advanced solid tumors                                                  No standard therapy availaible                                     NCT03295942                                                                   Active, not recruiting                                                  

  B7-H3                                                                                                          MGA271 (Enoblituzumab)                                   +/− Pembrolizumab (anti-PD1)                                                       I                                                                      Advanced solid tumors including TNBC                               No standard therapy available                                                 NCT02475213                                                             Active, not recruiting

  \+ Ipilimumab (anti-CTLA4)                                                                                     I                                                        Advanced solid tumors including TNBC                                               No standard therapy available                                          NCT02381314                                                        Active, not recruiting                                                                                                                                

  MGD009\                                                                                                        No                                                       I                                                                                  Advanced solid tumors including TNBC                                   ≥ 1 prior line                                                     NCT02628535                                                                   Recruiting                                                              
  (Orlotamab)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  MGA012 (anti-PD1)                                                                                              I                                                        Advanced solid tumors expressing B7-H3                                             No standard therapy available                                          NCT03406949                                                        Recruiting                                                                                                                                            

  MGC018                                                                                                         +/− MGA012 (anti-PD1)                                    I/II                                                                               Advanced solid tumors                                                  No standard therapy available                                      NCT03729596                                                                   Recruiting                                                              

  ICOS                                                                                                           JTX-2011                                                 +/− Nivolumab (anti-PD1)\                                                          I/II                                                                   Advanced solid tumors                                              No standard therapy availaible                                                NCT02904226                                                             Recruiting, safety results published \[[@B83-cancers-11-00628]\]
                                                                                                                                                                          +/− Ipilimumab (anti-CTLA4)\                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                                          +/− Pembrolizumab (anti-PD1)                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                 BMS-986226                                               +/− Nivolumab (anti-PD1) or Ipilimumab (anti-CTLA4)                                I/II                                                                   Advanced solid tumors                                              ≥ 1 prior line                                                                NCT03251924                                                             Recruiting

  4-1BB                                                                                                          PF-05082566\                                             \+ Trastuzumab -- Vinorelbine -- Avelumab (anti-PDL1)\                             II                                                                     Advanced Her2+ BC                                                  ≥ 1 prior line with progression under Trastuzumab - Pertuzumab                NCT03414658                                                             Recruiting
                                                                                                                 (Utolimumab)                                             + Trastuzumab -- Avelumab (anti-PDL1)                                                                                                                                                                                                                                                                                                                                              

  Cohort 1: + Trastuzumab -- Emtansine\                                                                          IB                                                       Advanced Her2+ BC                                                                  Cohort 1: ≥ 1 prior line with taxane and trastuzumab\                  NCT03364348                                                        Recruiting                                                                                                                                            
  Cohort 2: + Trastuzumab                                                                                                                                                                                                                                    Cohort 2: ≥ 2 prior lines                                                                                                                                                                                                                                                                       

  \+ Avelumab (anti-PDL1)                                                                                        IB/II                                                    Advanced solid tumors including TNBC                                               Any line                                                               NCT02554812                                                        Recruiting                                                                                                                                            

  Arm A: + Avelumab (Anti-PD-L1)\                                                                                I/II                                                     Advanced solid tumors                                                              No strandard therapy available                                         NCT03217747                                                        Recruiting                                                                                                                                            
  Arm C: + Avemulmab (anti-PD-L1) and PF-04518600 (anti-OX40)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  BMS-663513\                                                                                                    +/− Nivolumab (anti-PD1)                                 I/II                                                                               Advanced solid tumors                                                  Any line                                                           NCT02253992                                                                   Active, not recruiting                                                  
  (Urelumab)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  \+ SBRT -- Nivolumab (anti-PD1)                                                                                I                                                        Advanced solid tumors                                                              Any line                                                               NCT03431948                                                        Recruiting                                                                                                                                            

  No                                                                                                             I                                                        Advanced solid tumors                                                              No strandard therapy available                                         NCT01471210                                                        Completed, preliminary safety results published \[[@B84-cancers-11-00628]\]                                                                           

  \+ Nivolumab (anti-PD1)                                                                                        I                                                        Advanced solid tumors                                                              No strandard therapy available                                         NCT02534506                                                        Active, not recruiting                                                                                                                                

  \+ Nivolumab (anti-PD1)                                                                                        I/II                                                     Advanced solid tumors                                                              No strandard therapy available                                         NCT03792724                                                        Not yet recruiting                                                                                                                                    

  PRS-343                                                                                                        \+ Atezolizumab (anti-PDL1)                              IB                                                                                 Advanced solid tumors including Her2+ BC                               ≥ 2^nd^ line                                                       NCT03650348                                                                   Recruiting                                                              

  No                                                                                                             I                                                        Advanced solid tumors including Her2+ BC                                           No strandard therapy available                                         NCT03330561                                                        Recruiting                                                                                                                                            

  ADG106                                                                                                         No                                                       I                                                                                  Advanced solid tumors                                                  No strandard therapy available                                     NCT03802955                                                                   Recruiting                                                              

  No                                                                                                             I                                                        Advanced solid tumors                                                              No strandard therapy available                                         NCT03707093                                                        Recruiting                                                                                                                                            

  CD27/CD70                                                                                                      Anti-hCD70 CAR PBL                                       \+ Aldeskeukin (IL-2)                                                              I/II                                                                   Advanced solid tumors expressing CD70                              ≥ 2^nd^ line                                                                  NCT02830724                                                             Recruiting

  ARGX-110\                                                                                                      No                                                       I/II                                                                               Advanced solid tumors expressing CD70                                  No standard therapy available                                      NCT01813539                                                                   Active, not recruiting\                                                 
  (Cusatuzumab)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Safety results published \[[@B85-cancers-11-00628]\]                    

  CDX-1127 (Varlilumab)                                                                                          \+ ONT-10 (Immunovaccine)                                IB                                                                                 Advanced BC                                                            ≥ 2^nd^ line                                                       NCT02270372                                                                   Completed, no published results                                         

  OX40/OX40L                                                                                                     MOXR0916\                                                No                                                                                 I                                                                      Advanced solid tumors                                              No standard therapy available                                                 NCT02219724                                                             Active, not recruiting
                                                                                                                 (Vonlerolizumab)                                                                                                                                                                                                                                                                                                                                                                                                                            

  \+ Atezolizumab (anti-PDL1)                                                                                    IB                                                       Advanced solid tumors                                                              No standard therapy available                                          NCT02410512                                                        Active, not recruiting\                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                       Preliminary safety results published \[[@B86-cancers-11-00628]\]                                                                                      

  PF-04518600                                                                                                    \+ Avelumab (anti-PDL1)\                                 I/II                                                                               Advanced solid tumors                                                  No standard therapy available                                      NCT03217747                                                                   Recruiting                                                              
                                                                                                                 Or + Utolilumab (Anti-4-1BB) and Avelumab (anti-PDL1)\                                                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                 +/− Radiation                                                                                                                                                                                                                                                                                                                                                                                                                               

  MEDI6383                                                                                                       +/− MEDI4736 (anti-PDL1)                                 I                                                                                  Advanced solid tumors                                                  No standard therapy available\                                     NCT02221960                                                                   Completed, no published results                                         
                                                                                                                                                                                                                                                                                                                                    ≤ 5 prior lines                                                                                                                                                                                                          

  MEDI0562                                                                                                       +/− MEDI4736 (anti-PDL1)\                                I                                                                                  Advanced solid tumors                                                  No standard therapy available\                                     NCT02705482                                                                   Active, not recruiting                                                  
                                                                                                                 Or +/− Tremelilumab (anti-CTLA4)                                                                                                                                                                                   ≤ 3 prior lines                                                                                                                                                                                                          

  INCAGN01949                                                                                                    No                                                       I/II                                                                               Advanced solid tumors                                                  No standard therapy available                                      NCT02923349                                                                   Active, not recruiting                                                  

  +/− Nivolumab (anti-PD1)\                                                                                      I/II                                                     Advanced solid tumors (phase I)                                                    No standard therapy available                                          NCT03241173                                                        Active, not recruiting                                                                                                                                
  +/− Ipilimumab (anti-CTLA4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  GSK3174998                                                                                                     +/− Pembrolizumab (anti-PD1)                             I                                                                                  Advanced solid tumors                                                  No standard therapy available\                                     NCT02528357                                                                   Recruiting                                                              
                                                                                                                                                                                                                                                                                                                                    ≤ 5 prior lines                                                                                                                                                                                                          

  \+ GSK1795091 (TLR4 agonist)                                                                                   I                                                        Advanced solid tumors including BC but not TNBC                                    No standard therapy available                                          NCT03447314                                                        Recruiting                                                                                                                                            

  MEDI6469                                                                                                       \+ SBRT to liver or lung metastases                      I/II                                                                               Advanced BC                                                            ≥ 1 prior line                                                     NCT01862900                                                                   Completed, no published results                                         

  mRNA 2416                                                                                                      No                                                       I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT03323398                                                                   Recruiting                                                              

  BMS-986178                                                                                                     \+ intra-tumoral SD-101 (TLR9 agonist)                   I                                                                                  Advanced solid tumors                                                  ≥ 1 prior line                                                     NCT03831295                                                                   Recruiting                                                              

  +/− Nivolumab (anti-PD1) and/or Ipilimumab (anti-CTLA4)                                                        I/IIa                                                    Advanced solid tumors                                                              ≥ 1 prior line                                                         NCT02737475                                                        Recruiting                                                                                                                                            

  BTLA                                                                                                           NA                                                       NA                                                                                 NA                                                                     NA                                                                 NA                                                                            NA                                                                      NA

  TLR9                                                                                                           IMO-2125\                                                No                                                                                 Ib                                                                     Advanced solid tumors                                              Any line (previously treated with anti-PDL1 therapy if indicated)             NCT03052205                                                             Active, not recruiting\
                                                                                                                 (Tilsotolomid)\                                                                                                                                                                                                                                                                                                                                                                                                                             Preliminary safety results published \[[@B87-cancers-11-00628]\]
                                                                                                                 Intra-tumoral                                                                                                                                                                                                                                                                                                                                                                                                                               

  Agatolimod\                                                                                                    \+ Trastuzumab                                           I/II                                                                               Advanced Her2+ BC                                                      ≤ 3 lines                                                          NCT00043394                                                                   Completed, no published results                                         
  (CPG 7909; PF-3512676)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  \+ Trastuzumab                                                                                                 I/II                                                     Advanced Her2+ BC                                                                  Not specified                                                          NCT00031278                                                        Completed, no published results                                                                                                                       

  \+ Montanide® ISA-51 (immune modulator)\                                                                       I                                                        Localised solid tumors                                                             Neo-adjuvant or adjuvant chemotherapy authorised                       NCT00299728                                                        Completed, no published results                                                                                                                       
  + NY-ESO-l protein (therapeutic vaccine)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  \+ Montanide ISA 720 (immune modulator)\                                                                       I                                                        Advanced solid tumors expressing NY-ESO-1                                          ≥ 2^nd^ line                                                           NCT00819806                                                        Completed, no results published                                                                                                                       
  + Cyclophosphamide\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  + NY-ESO-1-derived Peptides or Protein (therapeutic vaccine)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  MGN1703                                                                                                        \+ Ipilimumab (anti-CTLA4)                               I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT02668770                                                                   Recruiting                                                              

  SD-101                                                                                                         \+ BMS 986178 (anti-OX40)                                I                                                                                  Advanced solid tumors                                                  ≥ 1 prior line                                                     NCT03831295                                                                   Recruiting                                                              

  \+ Pembrolizumab (anti-PD1)                                                                                    II                                                       Stage II or III BC                                                                 No prior treatment                                                     NCT01042379                                                        Recruiting                                                                                                                                            

  **Adenosine pathway**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  A2aR                                                                                                           NIR178                                                   +/− NZV930 (anti-CD73)\                                                            I/IB                                                                   Advanced solid tumors including TNBC                               No standard therapy available                                                 NCT03549000                                                             Recruiting
                                                                                                                                                                          +/− PDR001 (anti-PD1)                                                                                                                                                                                                                                                                                                                                                              

  \+ PDR001 (anti-PD1) and LAG525 (anti-LAG3)                                                                    I                                                        Advanced TNBC                                                                      ≤ 2 prior lines                                                        NCT03742349                                                        Recruiting                                                                                                                                            

  AZD4635                                                                                                        +/− Durvalumab (Anti-PDL1)                               I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT02740985                                                                   Recruiting                                                              

  AB928                                                                                                          \+ AB122 (anti-PD1)                                      I                                                                                  Advanced solid tumors                                                  No standard therapy available                                      NCT03629756                                                                   Recruiting                                                              

  +/− Pegylated liposomal doxorubicin                                                                            I/Ib                                                     Advanced TNBC                                                                      No standard therapy available                                          NCT03719326                                                        Recruiting                                                                                                                                            

  CPI-444                                                                                                        +/− Atezolizumab (anti-PDL1)                             I                                                                                  Advanced solid tumors including TNBC                                   ≥ 1 and ≤ 5 prior lines                                            NCT02655822                                                                   Recruiting                                                              

  +/− CPI-006 (anti-CD73)                                                                                        I/IB                                                     Advanced solid tumors including TNBC                                               ≥ 1 and ≤ 5 prior lines                                                NCT03454451                                                        Recruiting                                                                                                                                            

  CD73                                                                                                           SRF373\                                                  +/− PDR001 (anti-PD1)\                                                             I/IB                                                                   Advanced solid tumors including TNBC                               No standard therapy available                                                 NCT03549000                                                             Recruiting
                                                                                                                 (NZV930)                                                 +/− NIR178 (A2aR antagonist)                                                                                                                                                                                                                                                                                                                                                       

  CPI-006                                                                                                        +/− CPI-444 (A2aR antagonist)\                           I/IB                                                                               Advanced solid tumors including TNBC                                   ≥ 1 and ≤ 5 prior lines                                            NCT03454451                                                                   Recruiting                                                              
                                                                                                                 +/− Pembrolizumab (anti-PD1)                                                                                                                                                                                                                                                                                                                                                                                                                

  BMS-986179                                                                                                     +/− Nivolumab (anti-PD1)\                                I/IIA                                                                              Advanced solid tumors                                                  Any line                                                           NCT02754141                                                                   Recruiting, preliminary results published \[[@B88-cancers-11-00628]\]   
                                                                                                                 +/− rHuPH20 (Recombinant human hyaluronidase)                                                                                                                                                                                                                                                                                                                                                                                               

  MEDI9447\                                                                                                      +/− MEDI4736 (anti-PDL1)                                 I                                                                                  Advanced solid tumors                                                  Any line                                                           NCT02503774                                                                   Recruiting                                                              
  (Oleclumab)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  \+ Paclitaxel -- Carboplatin -- Durvalumab (anti-PDL1)                                                         I/II                                                     Advanced TNBC                                                                      1st line                                                               NCT03616886                                                        Recruiting                                                                                                                                            

  No                                                                                                             I                                                        Advanced solid tumors (Japanese population)                                        No standard therapy available                                          NCT03736473                                                        Active, not recruiting                                                                                                                                

  \+ NACT\                                                                                                       II                                                       Luminal B BC (neo-adjuvant setting)                                                Neo-adjuvant setting                                                   NCT03875573                                                        Not yet recruiting                                                                                                                                    
  + pre-operative surgery\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  + Durvalumab (anti-PDL1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  \+ Paclitaxel\                                                                                                 I/II                                                     Advanced TNBC                                                                      1st line                                                               NCT03742102                                                        Recruiting                                                                                                                                            
  + Durvalumab (anti-PDL1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  CD39                                                                                                           NA                                                       NA                                                                                 NA                                                                     NA                                                                 NA                                                                            NA                                                                      NA
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** LAG-3, lymphocyte-activation gene 3; TIM-3, T-cell immunoglobulin and mucin-domain containing-3; VISTA, V-domain Ig suppressor of T cell activation; TIGIT, T-cell immunoreceptor with Ig and ITIM domains; GITR, glucocorticoid-induced TNFR-related protein; B7-H3, B7 homolog 3; ICOS, Inducible T-cell costimulator; 4-1BB; CD27, cluster of differentiation 27; CD70, cluster of differentiation 70; BTLA, B- and T-lymphocyte attenuator; TLR9, Toll-like receptor 9; A2aR, A2A adenosine receptor; CD73, cluster of differentiation 73; CD39, cluster of differentiation 39; PD1, Programmed cell death 1; IDO1, Indoleamine 2, 3-dioxygenase 1; CTLA4, Cytotoxic T-Lymphocyte Associated Protein 4; PDL1, Programmed death-ligand 1, IL-2, Interleukine-2; SBRT, Stereotactic Body Radiation Therapy; NACT, neo-adjuvant chemotherapy; BC, breast cancer; TNBC, triple-negative breast cancer; Her2, human epidermal growth factor receptor 2.

cancers-11-00628-t003_Table 3

###### 

Expression and prognostic/predictive value of immune-related markers predominantly expressed by macrophages, NK and dendritic-cells in breast cancer (BC) patients.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Marker                            BC\                          Number of Patients                       Method                                       Positive/Overexpressing Cases                                                                                                  Prognostic/Predictive value                                                                                       Comments                                                                                                         Reference
                                    Subtype                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  --------------------------------- ---------------------------- ---------------------------------------- -------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------- ------------------------------
  **Macrophage-related**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  CSF-1/CSF-1R                      All                          581\                                     IHC                                          Positive cases:\                                                                                                               Positivity in node negative: worse OS (not in node positive patients)                                                                                                                                                              \[[@B264-cancers-11-00628]\]
                                                                 (301 node-negative, 280 node-positive)                                                node-negative 114/301 (38.9%)\                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                       node-positive 189/280 (67.5%)                                                                                                                                                                                                                                                                                                                                     

  All                               196                          IHC\                                     74% CSF-1+ and 58% CSF-1R+ tumors            CSF-1+ tumor cells: poor survival                                                                                              CSF-1+ tumor cells: more frequent metastases                                                                      \[[@B263-cancers-11-00628]\]                                                                                     
                                                                 in situ RNA detection                                                                                                                                                                                                                                                                                                                                                                                                                                   

  All                               572                          ELISA (circulating CSF1 levels)          NA                                           logCSF1: worse BCCS\                                                                                                           Cut-off: median serum CSF-1 expression                                                                            \[[@B262-cancers-11-00628]\]                                                                                     
                                                                                                                                                       high CSF-1: worse outcome in post-menopausal patients                                                                                                                                                                                                                                                                                                             

  All                               68                           IHC                                      NA                                           High CSF-1: worse DSS                                                                                                          High CSF-1R: marginally correlated to worse DSS                                                                   \[[@B261-cancers-11-00628]\]                                                                                     

  CCL2/CCR2                         All                          137                                      IHC                                          CCL2+ tumor cells: 30.7% in PTs vs 39.4% in paired recurrences\                                                                No correlation                                                                                                    Significantly higher CCL2 expression in tumor cells of recurrences (especially the early ones) compared to PTs   \[[@B267-cancers-11-00628]\]
                                                                                                                                                       CCL2+ stromal cells: 18.2% in PTs vs 22.6% in paired recurrences                                                                                                                                                                                                                                                                                                  

  All                               427                          IHC                                      NA                                           Stromal but not epithelial CCL2 expression: worse RFS in basal-like subtype                                                    Stromal CCL2 remained an independent factor of worse prognosis in basal-like subtype                              \[[@B268-cancers-11-00628]\]                                                                                     

  All                               63                           IHC                                      NA                                           CCR2 expression in tumor cells: worse DFS, MFS and OS                                                                          CCR2 expression in tumor cells and CCL2 expression in stromal cells associated with higher risk of metastasis.\   \[[@B269-cancers-11-00628]\]                                                                                     
                                                                                                                                                                                                                                                                                      CCR2 expression in tumor cells remained an independent factor of worse MFS                                                                                                                                                         

  All                               151\                         IHC                                      CCL2 high: 65/135 (48.1%)\                   CCL2 high: worse RFS                                                                                                           High combined CCL2/VEGF expression was independently associated with worse RFS                                    \[[@B270-cancers-11-00628]\]                                                                                     
                                    (135 evaluable)                                                       CCL2 low: 70/135 (51.9%)                                                                                                                                                                                                                                                                                                                                                                                       

  All                               3554\                        RNA-seq                                  NA                                           High mRNA CCL2 expression: better RFS in basal-like, HER2-enriched and luminal-B subtypes (median cutoff of mRNA expression)   No significant association between RFS and expression of CCL2 mRNA in the whole cohort and in luminal-A subtype   \[[@B271-cancers-11-00628]\]                                                                                     
                                    (TCGA and kmplot.com)                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  CD40                              All                          181                                      IHC                                          Cytoplasmic tumor cell expression: 53%\                                                                                        CD40 cytoplasmic positivity: better OS                                                                            Positive association of CD40 cytoplasmic expression in HR+ breast tumors                                         \[[@B272-cancers-11-00628]\]
                                                                                                                                                       Membrane tumor cell expression: 7.7%\                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                       Nuclear tumor cell expression: 81%                                                                                                                                                                                                                                                                                                                                

  **NK cell-related**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  CD94/NKG2A                        All                          28\                                      Flow cytometry                               NA                                                                                                                             NA                                                                                                                High expression of NKG2A in NK cells of tumor-draining lymph nodes described\                                    \[[@B273-cancers-11-00628]\]
                                                                 (TDLN)                                                                                                                                                                                                                                                                                                                                 NKG2A+ NK cells correlated to locally advanced disease                                                           

  NKG2D ligands (MICBAB, ULBP1-5)   All                          677                                      IHC                                          Tumor cell expression:\                                                                                                        High MIC-AB and ULBP-2 expression better RFS                                                                      Combined low expression of MIC-AB and ULBP-2 correlated to worse RFS                                             \[[@B274-cancers-11-00628]\]
                                                                                                                                                       MIC-AB: 50%\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                       ULBP-1: 90%\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                       ULBP-2: 99%\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                       ULBP-3: 100%\                                                                                                                                                                                                                                                                                                                                                     
                                                                                                                                                       ULBP-4: 26%\                                                                                                                                                                                                                                                                                                                                                      
                                                                                                                                                       ULBP-5: 90%                                                                                                                                                                                                                                                                                                                                                       

  **Dendritic cell-related**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  IDO                               All (Pakistani population)   100                                      IHC                                          100% positive\                                                                                                                 Medium and high IDO: worse OS                                                                                     IDO expression correlated to TNBC                                                                                \[[@B275-cancers-11-00628]\]
                                                                                                                                                       24/100 low IDO (24%)\                                                                                                                                                                                                                                                                                                                                             
                                                                                                                                                       27/100 medium IDO (27%)\                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                       49/100 high IDO (49%)                                                                                                                                                                                                                                                                                                                                             

  All                               203                          IHC                                      100% positive\                               General population: no difference in OS\                                                                                       IDO expression correlated to ER+                                                                                  \[[@B276-cancers-11-00628]\]                                                                                     
                                                                                                          108/203 low IDO (53.2%)\                     ER+ IDO intermediate/high: better OS\                                                                                                                                                                                                                                                                                                                             
                                                                                                          95/203 intermediate and high IDO (46.8%)     Node-positive IDO intermediate/high: better DSS                                                                                                                                                                                                                                                                                                                   

  All                               26 primary tumor + TDLN\     IHC                                      IDO positivity:\                             IDO expression: statistically not significant worse OS and TTP                                                                 IDO expression correlated to advanced stages, lymph-node metastasis and Treg infiltration\                        \[[@B277-cancers-11-00628]\]                                                                                     
                                    10 benign lesions                                                     PT: 12/26 (46.15%)\                                                                                                                                                         No expression in healthy adjacent tissue                                                                                                                                                                                           
                                                                                                          TDLN: 19/26 (73.08%)\                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                          Benign lesions: 1/10 (10%)                                                                                                                                                                                                                                                                                                                                                                                     

  All                               155                          IHC                                      Stromal positivity (\>5%): 49/155 (31%)\     IDO positivity: better OS                                                                                                      IDO positivity correlated to absence of lymph-node metastasis, ER- and TNBC                                       \[[@B278-cancers-11-00628]\]                                                                                     
                                                                                                          Epithelial positivity (\>10%) 24/155 (15%)                                                                                                                                                                                                                                                                                                                                                                     

  All                               242 primary tumor\           IHC                                      IDO positivity:\                             NA                                                                                                                             IDO positivity correlated to high grade and TNBC\                                                                 \[[@B279-cancers-11-00628]\]                                                                                     
                                    20 TDLN\                                                              PT: 34/242 (14%)\                                                                                                                                                           Co-expression of IDO in 70% of PDL-1+ cases                                                                                                                                                                                        
                                    19 metastasis                                                         TDLN: 1/20 (5%)\                                                                                                                                                                                                                                                                                                                                                                                               
                                                                                                          Metastasis: 0/19 (0%)                                                                                                                                                                                                                                                                                                                                                                                          

  All                               65                           IHC                                      IDO positivity: 42/65 (64.6%)                IDO expression: worse OS and PFS in UA but not MA                                                                              IDO expression correlated to high grade, lymph-node metastastasis                                                 \[[@B280-cancers-11-00628]\]                                                                                     

  All                               54                           IHC                                      IDO positivity: 27/54 (68.5%)                IDO expression: worse response to NACT and statistically not significant worse PFS and OS                                      IDO expression correlated to advanced stages, lymph-node metastasis                                               \[[@B281-cancers-11-00628]\]                                                                                     

  All                               129 PT\                      IHC                                      IDO expression:\                             NA                                                                                                                             IDO expression correlated to lymph-node metastasis, ER-, TNBC and PD-1 expression                                 \[[@B282-cancers-11-00628]\]                                                                                     
                                    10 normal LN\                                                         PT: NA\                                                                                                                                                                                                                                                                                                                                                                                                        
                                    17 metastatic LN                                                      Normal lymph-nodes 80%\                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                          Metastatic lymph nodes 88.2%                                                                                                                                                                                                                                                                                                                                                                                   

  All                               54 PT\                       qRT-PCR                                  NA                                           NA                                                                                                                             IDO expression reduced in tumor compared to healthy tissue\                                                       \[[@B283-cancers-11-00628]\]                                                                                     
                                    11 healthy controls                                                                                                                                                                                                                               IDO expression in tumor correlated to advanced stage                                                                                                                                                                               

  All                               46                           IHC                                      IDO high: 26/46 (56.5%)                      IDO high: worse response to NACT and worse PFS and OS                                                                          IDO high correlated to advanced stage and lymph-node metastasis                                                   \[[@B284-cancers-11-00628]\]                                                                                     

  HR+                               362                          IHC                                      IDO expression 276/362 (76.2%)               IDO expression: worse OS                                                                                                       IDO expression not correlated to clinico-pathological characteristics\                                            \[[@B285-cancers-11-00628]\]                                                                                     
                                                                                                                                                                                                                                                                                      IDO expression negatively correlated to B-cell infiltration                                                                                                                                                                        

  All                               202                          IHC                                      NA                                           IDO high (expression by CAFs): worse DSS and MFS                                                                                                                                                                                                 \[[@B286-cancers-11-00628]\]                                                                                     

  All                               91 PT\                       IHC                                      IDO expression:\                             NA                                                                                                                             IDO expression correlated to advanced stage                                                                       \[[@B287-cancers-11-00628]\]                                                                                     
                                    21 benign lesions\                                                    PT: 55/91 (60%)\                                                                                                                                                                                                                                                                                                                                                                                               
                                    10 healthy controls                                                   Benign lesions 9/21 (43%)\                                                                                                                                                                                                                                                                                                                                                                                     
                                                                                                          Healthy controls 2/10 (20%)                                                                                                                                                                                                                                                                                                                                                                                    

  All                               85                           IHC                                      NA                                           NA                                                                                                                             IDO expression correlated to Treg infiltration and lymph-node metastasis                                          \[[@B288-cancers-11-00628]\]                                                                                     

  All                               5                            IHC                                      IDO expression 5/5 (100%)                    NA                                                                                                                                                                                                                                               \[[@B289-cancers-11-00628]\]                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CSF-1R, colony-stimulating factor 1 receptor; CSF-1, colony-stimulating factor 1; CCL2, C-C Motif Chemokine Ligand 2; CCR2, C-C Motif Chemokine Receptor 2; IDO, Indoleamine 2,3-dioxygenase; NK-cells, natural-killer cells; CD40, cluster of differentiation 40; CD94, cluster of differentiation 94; NKG2A, NK group member 2A; NKG2D, NK group member 2D; VEGF, vascular endothelial growth factor; IHC, immunohistochemistry; qRT-PCR, quantitative real-time polymerase chain reaction; T-reg, T-regulatory cells; OS, overall survival; PFS, progression-free survival; MFS, metastasis-free survival; RFS, relapse-free survival; TTP, time-to-progression; DSS, disease-specific survival; BCCS, breast cancer-specific survival; PT, primary tumor; NACT, neoadjuvant chemotherapy; PD-1, programmed death 1; TNBC, triple-negative breast cancer; ER, estrogen receptor; HR, hormone receptor; CAFs, cancer-associated fibroblasts; MICBA/B, MHC class I chain-related protein A and B; ULBP1-5, UL binding protein 1-5; LN, lymph node; TDLN, tumor-draining lymph node; NA, not available.

cancers-11-00628-t004_Table 4

###### 

Ongoing clinical trials potentially including breast cancer patients for targeting of immune-related markers predominantly expressed on macrophages, NK and dendritic cells.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target                                                                            Drug                                                                   Other Agent(s)                                                 Phase                                                                          Disease                                                        Line                                                                                        NCT Identifier                                                                  Trial Status
  --------------------------------------------------------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------------------ -------------------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ---------------------------------
  **TAM-stimulatory markers**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  ***CSF-1/CSF-1R***                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  CSF-1R/CSF-1 inhibitors                                                           PLX 3397\                                                              \+ Eribulin                                                    Ib/II                                                                          Metastatic breast cancer                                       ≥ 1 prior line                                                                              NCT01596751                                                                     Active, not recruiting
                                                                                    (Pexidartinib)                                                                                                                                                                                                                                                                                                                                                                                                                                                  

  No                                                                                I                                                                      Advanced solid tumors                                          No standard therapy available                                                  NCT01004861                                                    Active, not recruiting                                                                                                                                                      

  +/− Paclitaxel                                                                    Ib                                                                     Advanced solid tumors                                          Not specified                                                                  NCT01525602                                                    Completed, no published results                                                                                                                                             

  ARRY-382                                                                          +/− Pembrolizumab (anti-PD1)                                           Ib/II                                                          Advanced solid tumors including TNBC (phase Ib)                                No standard therapy available                                  NCT02880371                                                                                 Recruiting                                                                      

  No                                                                                I                                                                      Advanced or metastatic solid tumors                            No standard therapy available                                                  NCT01316822                                                    Completed, no published results                                                                                                                                             

  BLZ945                                                                            +/− PDR001 (anti-PD1)                                                  I                                                              Advanced solid tumors including TNBC                                           Not specified                                                  NCT02829723                                                                                 Recruiting                                                                      

  Anti CSF-1R antibodies                                                            LY3022855\                                                             No                                                             I                                                                              Advanced BC                                                    ≥ 1 prior line                                                                              NCT02265536                                                                     Completed, no published results
                                                                                    (IMC-CS4)                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  \+ Durvalumab (anti-PDL1) or Tremelimumab (anti-CTLA4)                            I                                                                      Advanced solid tumors                                          Not specified                                                                  NCT02718911                                                    Completed, no published results                                                                                                                                             

  No                                                                                I                                                                      Advanced solid tumors                                          No standard therapy available                                                  NCT01346358                                                    Completed, safety results published \[[@B290-cancers-11-00628]\]                                                                                                            

  RO5509554\                                                                        \+ Atezolizumab (anti-PDL1)                                            I                                                              Advanced solid tumors including TNBC                                           Not specified                                                  NCT02323191                                                                                 Recruiting                                                                      
  (Emactuzumab)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  +/− Paclitaxel                                                                    I                                                                      Advanced solid tumors                                          No standard therapy available                                                  NCT01494688                                                    Completed, preliminary safety and activity results published \[[@B291-cancers-11-00628]\]                                                                                   

  \+ RO7009789 (CD40 agonist)                                                       Ib                                                                     Advanced solid tumors including TNBC                           No standard therapy available                                                  NCT02760797                                                    Completed, no published results                                                                                                                                             

  AMG820                                                                            No                                                                     I                                                              Advanced solid tumors                                                          Not specified                                                  NCT01444404                                                                                 Completed, no published results                                                 

  SNDX-6352                                                                         Phase Ia: SNDX-6352 monotherapy\                                       I                                                              Advanced solid tumors                                                          ≥ 1 prior line and no standard therapy available               NCT03238027                                                                                 Recruiting                                                                      
                                                                                    Phase Ib: + Durvalumab (anti-PDL1)                                                                                                                                                                                                                                                                                                                                                                                                                              

  Cabiralizumab (BMS-986227, FPA008)                                                +/− Nivolumab (anti-PD1)                                               I                                                              Advanced malignancies                                                          No standard therapy available                                  NCT03158272                                                                                 Recruiting                                                                      

  \+ Nivolumab (anti-PD1) and SBRT                                                  I                                                                      Advanced malignancies                                          No standard therapy available                                                  NCT03431948                                                    Recruiting                                                                                                                                                                  

  PD 0360324 (M-CSF mAb)                                                            \+ Avelumab (anti-PDL1)                                                Ib/II                                                          Advanced solid tumors including TNBC                                           No standard therapy available                                  NCT02554812                                                                                 Recruiting                                                                      

  **CCL2/CCR2**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  CCR2 antagonist                                                                   PF-04136309                                                            \+ Avelumab (anti-PDL1)\                                       Ib/II                                                                          Advanced solid tumors including TNBC                           No standard therapy available                                                               NCT02554812                                                                     Recruiting
                                                                                                                                                           +Utomilumab (anti-4-1BB)                                                                                                                                                                                                                                                                                                                                                                 

  **CD47 -- SIRPα**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Anti-CD47 antibodies                                                              Hu5F9-G4                                                               \+ Cetuximab (anti-EGFR)                                       Ib/II                                                                          Advanced solid tumors including BC (phase Ib)                  ≥ 1 prior line                                                                              NCT02953782                                                                     Recruiting

  +Avelumab (anti-PDL1)                                                             Ib                                                                     Advanced solid tumors                                          Not specified                                                                  NCT03558139                                                    Recruiting                                                                                                                                                                  

  CC-90002                                                                          No                                                                     I                                                              Advanced solid tumors                                                          No standard therapy available                                  NCT02367196                                                                                 Recruiting                                                                      

  IBI188                                                                            No                                                                     Ia                                                             Advanced solid tumors                                                          No standard therapy available                                  NCT03763149                                                                                 Recruiting                                                                      

  No                                                                                I                                                                      Advanced solid tumors                                          No standard therapy available                                                  NCT03717103                                                    Recruiting                                                                                                                                                                  

  AO-176                                                                            No                                                                     I                                                              Advanced solid tumors                                                          No standard therapy available                                  NCT03834948                                                                                 Recruiting                                                                      

  SRF231                                                                            No                                                                     I/Ib                                                           Advanced solid tumors                                                          No standard therapy available                                  NCT03512340                                                                                 Recruiting                                                                      

  SIRPα-IgG1-Fc                                                                     TTI-621\                                                               +/− PD1/PDL1 Inhibitor                                         I                                                                              Advanced solid tumors with percutaneously accessible lesions   No standard therapy available                                                               NCT02890368                                                                     Recruiting
                                                                                    (intra-tumoral injection)                                                                                                                                                                                                                                                                                                                                                                                                                                       

  ALX148                                                                            +/− Trastuzumab or Pembrolizumab (anti-PD1) or Rituximab (anti-CD20)   I                                                              Advanced solid tumors                                                          No standard therapy available                                  NCT03013218                                                                                 Recruiting, preliminary safety results published \[[@B292-cancers-11-00628]\]   

  **TAM-inhibitory markers**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  CD40 (agonists)                                                                   CP-870,893                                                             No                                                             I                                                                              Advanced solid tumors                                          No standard therapy available                                                               NCT02225002                                                                     Completed, no published results

  No                                                                                I                                                                      Advanced solid tumors                                          Patients who had clinical benefit following a single infusion of CP-870, 893   NCT02157831                                                    Completed                                                                                                                                                                   

  RO7009789\                                                                        \+ Atezolizumab (anti PDL1)                                            Ib                                                             Advanced solid tumors                                                          No standard therapy available                                  NCT02304393                                                                                 Recruiting                                                                      
  Selicrelumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  \+ Emactuzumab (anti-CSF-1R)                                                      I                                                                      Advanced solid tumors including TNBC                           No standard therapy available                                                  NCT02760797                                                    Completed, no published results                                                                                                                                             

  \+ Vanucizumab (anti-VEGF-A and angiopoietin-2)                                   I                                                                      Metastatic solid tumors                                        Not specified                                                                  NCT02665416                                                    Recruiting                                                                                                                                                                  

  ADC-1013\                                                                         No                                                                     I                                                              Advanced solid tumors                                                          Not specified                                                  NCT02379741                                                                                 Completed, no published results                                                 
  (intra-tumoral or intra-venous injection)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  JNJ-64457107                                                                      No                                                                     I                                                              Advanced solid tumors                                                          Not specified                                                  NCT0282909                                                                                  Recruiting                                                                      

  TLR7\                                                                             Imiquimod                                                              \+ Cyclophosphamide and Radiotherapy                           I/II                                                                           Advanced BC with skin metastases                               Any line                                                                                    NCT01421017                                                                     Completed, no published results
  (agonists)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  **NK cell-inhibitory markers**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  CD94/\                                                                            IPH2201                                                                \+ Durvalumab (anti-PDL1)                                      I/II                                                                           Advanced solid tumors                                          Any line                                                                                    NCT02671435                                                                     Recruiting
  NKG2A                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  KIR family                                                                        Lirilumab\                                                             +Nivolumab (anti-PD1)\                                         I                                                                              Advanced and/or metastatic solid tumors                        Not specified                                                                               NCT03203876                                                                     Active, not recruiting
                                                                                    (anti-KIR2DL1,2,3 antibody)                                            Or + Nivolumab (anti-PD1) and Ipilimumab (anti-CTLA4)                                                                                                                                                                                                                                                                                                                                    

  +Nivolumab (anti-PD1)                                                             I/II                                                                   Advanced solid tumors                                          ≥ 1 and ≤ 5 prior lines                                                        NCT01714739                                                    Active, not recruiting                                                                                                                                                      

  **IDO**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Small-molecule inhibitor of IDO-1                                                 Epacadostat\                                                           \+ INCB01158\                                                  I/II                                                                           Advanced solid tumors                                          No standard therapy available                                                               NCT03361228                                                                     Active, not recruiting
                                                                                    (INCB024360)                                                           (arginase inhibitor)\                                                                                                                                                                                                                                                                                                                                                                    
                                                                                                                                                           +/− Pembrolizumab (anti-PD1)                                                                                                                                                                                                                                                                                                                                                             

  \+ Pembrolizumab (anti-PD1)                                                       I/II                                                                   Advanced or metastatic solid tumors including TNBC (phase I)   ≥ 1 prior line                                                                 NCT02178722                                                    Active, not recruiting\                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                                        Preliminary safety and efficacy results published \[[@B293-cancers-11-00628]\]                                                                                              

  \+ Sirolimus (mTOR inhinitor)                                                     I                                                                      Advanced solid tumors                                          ≥ 1 prior line and no standard therapy available                               NCT03217669                                                    Recruiting                                                                                                                                                                  

  +Nivolumab (anti-PD1) and Ipilimumab (anti-CTLA4) (group A)\                      I/II                                                                   Advanced solid tumors                                          No standard therapy available (phase I)\                                       NCT03347123                                                    Active, not recruiting                                                                                                                                                      
  + Nivolumab (anti-PD1) + lirilumab (anti-KIR) (group B)                                                                                                                                                                 ≥ 1 prior line (phase II)                                                                                                                                                                                                                                                                                                 

  \+ Durvalumab (anti-PDL1)                                                         I/II                                                                   Advanced solid tumors                                          ≥ 1 prior line                                                                 NCT02318277                                                    Active, not recruiting                                                                                                                                                      

  \+ Pembrolizumab (anti-PD1)\                                                      I/II                                                                   Advanced solid tumors                                          Not specified                                                                  NCT03085914                                                    Active, not recruiting                                                                                                                                                      
  And mFOLFOX6\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Or (anti-PD1) Gemcitabine and\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Nab-Paclitaxel\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Or Carboplatin and Paclitaxel\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Or Pemetrexed, and Platinium agent\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Or Cyclophosphamide\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Or Gemcitabine and Platinium agent\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Or Platinium agent and 5-Fu                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  +/− Pembrolizumab (anti-PD1)\                                                     I                                                                      Advanced solid tumors (Japanese population)                    No standard therapy available                                                  NCT02862457                                                    Active, not recruiting\                                                                                                                                                     
  Or +/−Pembrolizumab (anti-PD1) and Carboplatin or Cisplatin and Paclitaxel\                                                                                                                                                                                                                                                                                           Preliminary safety and efficacy results published \[[@B294-cancers-11-00628]\]                                                                                              
  Or +/− Pembrolizumab (anti-PD1) and Carboplatin and Paclitaxel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  \+ Pembrolizumab (anti-PD1) and Azacitidine (DNA methyl transferase inhibitor)\   I/II                                                                   Advanced solid tumors                                          No standard therapy available                                                  NCT02959437                                                    Active, not recruiting                                                                                                                                                      
  Or + INCB057643 (BET inhibitor) + Pembrolizumab (anti-PD1)\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Or + INCB059872 (LSD1 inhibitor) and Pembrolizumab (anti-PD1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  No                                                                                I                                                                      Advanced solid tumors                                          No standard therapy available                                                  NCT01195311                                                    Completed, safety results published \[[@B295-cancers-11-00628]\]                                                                                                            

  \+ Pembrolizumab (anti-PD1) and INCAGN01876 (anti-GITR)                           I/II                                                                   Advanced solid tumors                                          No standard therapy avaialble                                                  NCT03277352                                                    Active, not recruiting                                                                                                                                                      

  \+ Itacitinib (JAK inhibitor)                                                     I                                                                      Advanced solid tumors including TNBC                           No standard therapy available                                                  NCT02559492                                                    Active, not recruiting                                                                                                                                                      

  No                                                                                Ib                                                                     Resectable metastatic solid tumors                             Eligible for surgical resection and no standard therapy available              NCT03471286                                                    Recruiting                                                                                                                                                                  

  GDC-0919\                                                                         \+ Atezolizumab (anti-PD-1)                                            Ib                                                             Advanced solid tumors                                                          ≥ 1 prior line                                                 NCT02471846                                                                                 Active, not recruiting                                                          
  (navoximod)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  NLG802                                                                            No                                                                     I                                                              Advanced solid tumors                                                          Not specified                                                  NCT03164603                                                                                 Recruiting                                                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** TAM, tumor-associated macrophages; CSF-1R, colony-stimulating factor 1 receptor; CSF-1, colony-stimulating factor 1; PD-1, programmed death 1; PD-L1, programmed death ligand 1; SBRT, stereotactic body radiation therapy; CCL2, C-C Motif Chemokine Ligand 2; CCR2, C-C Motif Chemokine Receptor 2; CD47, cluster of differentiation 47; SIRPα, signal regulatory protein alpha; IDO, Indoleamine 2,3-dioxygenase; TLR7, toll-like receptor 7; NK-cells, natural-killer cells; CD40, cluster of differentiation 40; CD94, cluster of differentiation 94; KIR, Killer Immunoglobin Receptors; NKG2A, NK group member 2A; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; KIR2DL1, Killer cell immunoglobulin-like receptor 2DL1; JAK, janus kinase; mTOR: mammalian target of rapamycin; BC, breast cancer; TNBC, triple-negative breast cancer; LSD1, lysine specific demethylase 1; BET, Bromodomain and Extra-Terminal motif; EGFR, epidermal growth factor receptor; VEGF-A, vascular endothelial growth factor A.
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###### 

Overview of immune-related markers' characteristics including origin of expression and their role in anti-tumor immunity.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Marker       Types of Cells Expressed                                                                                                       Function on Anti-tumor Immunity
  ------------ ------------------------------------------------------------------------------------------------------------------------------ ---------------------------------
  LAG-3        Effector T-cells, Tregs, NK-cells, B-cells, dendritic cells (DC)                                                               Co-inhibitory

  TIM-3        CD8+, CD4+ T helper 1 cells (Th1 cells), Tregs, NK cells, DC, monocytes, macrophages                                           Co-inhibitory

  VISTA        CD8+, CD4+ T-cells, Tregs, NK cells, DC, monocytes, macrophages, granulocytes                                                  Co-inhibitory

  TIGIT        Effector, memory, follicular helper (Tfh) T-cells, Tregs, NK-cells                                                             Co-inhibitory

  GITR         T-cells                                                                                                                        Co-stimulatory

  B7-H3        T-cells, antigen-presenting cells (APC), NK-cells                                                                              Co-stimulatory\
                                                                                                                                              Co-inhibitory

  ICOS         T-cells                                                                                                                        Co-stimulatory\
                                                                                                                                              Co-inhibitory

  4-1BB        Effector, helper T-cells, Tregs, B-cells, NK-cells, DC, neutrophils, eosinophils,\                                             Co-stimulatory
               mast cells, monocytes, macrophages                                                                                             

  CD27         T-cells, B-cells, NK-cells                                                                                                     Co-stimulatory

  OX40         Tregs, neutrophils, NK-cells and NKT-cells, CD4+ and CD8+ T-cells (upon TCR stimulation)                                       Co-stimulatory

  BTLA         T-cells, B-cells, Tfh cells, macrophages, DC, NKT-cells, NK-cells                                                              Co-inhibitory

  A2aR         T-cells, NKT-cells, B-cells, monocytes, macrophages, DC, NK-cells, mast cells, eosinophils, platelets                          Co-inhibitory

  CD73         B-cells, CD8+, CD4+ T-cells, Tregs, neutrophils, MDSC, monocytes, macrophages, DC, NK-cells, endothelial cells, cancer cells   Co-inhibitory

  CD39         Platelets, endothelial cells, cancer cells                                                                                     Co-inhibitory

  CCR2         Monocytes, macrophages                                                                                                         Co-inhibitory

  CD47         Cancer cells                                                                                                                   Co-inhibitory

  CD40         APC, macrophages                                                                                                               Co-stimulatory

  CD94/NKG2A   NK-cells, CD8+ T-cells                                                                                                         Co-inhibitory

  NKG2D        NK-cells                                                                                                                       Co-stimulatory

  IDO          Cancer cells, stromal dendritic-like cells, myoepithelial cells                                                                Co-inhibitory
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
